Anticoagulant Use, Safety and Effectiveness for Ischemic Stroke Prevention in Nursing Home Residents with Atrial Fibrillation by Alcusky, Matthew
University of Massachusetts Medical School 
eScholarship@UMMS 
GSBS Dissertations and Theses Graduate School of Biomedical Sciences 
2019-06-05 
Anticoagulant Use, Safety and Effectiveness for Ischemic Stroke 
Prevention in Nursing Home Residents with Atrial Fibrillation 
Matthew Alcusky 
University of Massachusetts Medical School 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/gsbs_diss 
 Part of the Cardiovascular Diseases Commons, Clinical Epidemiology Commons, Epidemiology 
Commons, and the Health Services Administration Commons 
Repository Citation 
Alcusky M. (2019). Anticoagulant Use, Safety and Effectiveness for Ischemic Stroke Prevention in Nursing 
Home Residents with Atrial Fibrillation. GSBS Dissertations and Theses. https://doi.org/10.13028/tfcw-
vx13. Retrieved from https://escholarship.umassmed.edu/gsbs_diss/1034 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in GSBS Dissertations and 











ANTICOAGULANT USE, SAFETY AND EFFECTIVENESS FOR ISCHEMIC 


















Submitted to the Faculty of the 
University of Massachusetts Graduate School of Biomedical Sciences, Worcester 
in partial fulfillment of the requirements for the degree of 
 
 





June 5, 2019 
 






ANTICOAGULANT USE, SAFETY AND EFFECTIVENESS FOR ISCHEMIC 
STROKE PREVENTION IN NURSING HOME RESIDENTS WITH ATRIAL 
FIBRILLATION 
 





This work was undertaken in the Graduate School of Biomedical Sciences Doctoral 
Program in Clinical and Population Health Research under the mentorship of 
 
________________________________________________________________ 
Kate L. Lapane, Ph.D., Thesis Advisor 
 
________________________________________________________________ 
Jennifer Tjia, M.D., MSCE, Member of Committee 
 
________________________________________________________________ 
David D. McManus, M.D., ScM, Member of Committee 
 
________________________________________________________________ 
Anthony Nunes, Ph.D., Member of Committee 
 
________________________________________________________________ 
Colleen Maxwell, Ph.D., External Member of Committee 
 
________________________________________________________________ 
Stephenie C. Lemon, Ph.D., Chair of Committee 
 
________________________________________________________________ 
Mary Ellen Lane, Ph.D. 
Dean of the Graduate School of Biomedical Sciences 
 






I am grateful for the support of several individuals whose contributions were 
critical to the completion of this dissertation. 
First, I would like to thank Dr. Kate L Lapane for her mentorship. Dr. Lapane’s 
selfless and unwavering commitment to the success of her mentees is worthy of much 
admiration, and I am supremely grateful to have had the opportunity to learn from her 
throughout this dissertation and I look forward to continuing to learn from her wisdom. 
Her encouragement and guidance inspire achievement and well-being (personal and 
professional) that exceeds far beyond normative expectations. 
I am also grateful to my dissertation committee of Jennifer Tjia, MD, MSCE; 
David McManus, MD, ScM; Stephenie Lemon, PhD; Anthony Nunes, PhD; and Colleen 
Maxwell, PhD, as well as my Thesis Research Advisory Committee and Comprehensive 
Project Committee members Jonggyu Baek, PhD, and Robert Goldberg, PhD, for their 
thoughtful input from the conceptualization to the dissemination stages of this 
dissertation.  
I would like to express my sincere appreciation for the support and guidance of 
my clinical colleagues and coauthors whose input has greatly improved the quality of my 
dissertation research, including Anne L. Hume, PharmD, and Marc Fisher, MD.  
In parallel to my dissertation, I have been fortunate to have had the opportunity to 
engage in applied research with exceptional individuals and renowned leaders in health 
policy, health services research, and biostatistics serving on the Department of Population 





mentorship of Jay Himmelstein, MD, MPH, Arlene Ash, PhD, and Eric Mick, PhD, and 
of the support from Department leadership including Catarina Kiefe, PhD, MD, and 
Jeroan Allison, MD, MS.   
I also owe a tremendous thanks to the faculty and staff of the Clinical and 
Population Health Research Program/ Department of Population and Quantitative Health 
Sciences, especially Dr. William Jesdale, Dr. Christine Ulbricht, Dr. Shao-Hsien Liu, Dr. 
Catherine Dube, Kelley Baron, Sandy Stankus, Judi Saber, and James Thompson. I 
would also like to thank my fellow CPHR students who have broadened the scope of my 
learning experiences in the program to encompass disciplines far beyond those on which 
I have chosen to focus. 
 Finally, I would like to convey my heartfelt appreciation to my family and to 
Alyssa Cass. Without their patience and encouragement, this considerable undertaking 








Fewer than one-third of nursing home residents with atrial fibrillation were treated with 
the only available oral anticoagulant, warfarin, historically. Management of atrial 
fibrillation has transformed in recent years with the approval of 4 direct-acting oral 
anticoagulants (DOACs) since 2010. 
Methods  
Using the national Minimum Data Set 3.0 linked to Medicare Part A and D claims, we 
first described contemporary (2011-2016) warfarin and DOAC utilization in the nursing 
home population (Aim 1). In Aim 2, we linked residents to nursing home and county 
level data to study associations between resident, facility, county, and state characteristics 
and anticoagulant treatment. Using a new-user active comparator design, we then 
compared the incidence of safety (i.e., bleeding), effectiveness (i.e., ischemic stroke), and 
mortality outcomes between residents initiating DOACs versus warfarin (Aim 3). 
Results 
The proportion of residents with atrial fibrillation receiving treatment increased from 
42.3% in 2011 to 47.8% as of December 31, 2016, at which time 48.2% of treated 
residents received DOACs. Demographic and clinical characteristics of residents using 
DOACs and warfarin were similar in 2016. Half of the 8,734 DOAC users received 






Compared with warfarin, bleeding rates were lower and ischemic stroke rates were higher 
for apixaban users. Ischemic stroke and bleeding rates for dabigatran and rivaroxaban 
were comparable to warfarin. Mortality rates were lower versus warfarin for each DOAC. 
Conclusions 
In nursing homes, DOACs are being used commonly and with equal or greater benefit 
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Atrial Fibrillation in the United States 
The number of people with atrial fibrillation is on the rise, driven by increases in 
the prevalence of certain atrial fibrillation risk factors (e.g., obesity, diabetes),1–3 
population growth, and the overall aging of the population.4 For example, in the United 
States, ~ 6.1 million adults had diagnosed atrial fibrillation in 2010,4 which is projected to 
increase to 12.1 million by 2050.4 The age and sex-adjusted incidence of atrial fibrillation 
increased 21% from 1980 to 2000.4 Ischemic stroke risk increases 5-fold in the presence 
of atrial fibrillation.5 Ischemic strokes caused by atrial fibrillation are more severe on 
average than other etiologies.6–8 In adults aged 80-89 years, atrial fibrillation is responsible 
for one in four strokes.4,5 Ischemic stroke has devastating consequences for patients’ 
functional independence, cognitive status, and quality of life,9–11 effects which are more 
severe at older ages.12 After a stroke, patients lose the equivalent of two activities of daily 
living11 and quality of life is diminished.10 Incident stroke is associated with an acute 
decline in measures of global cognition, new learning, and verbal memory, and a sustained 
increase in the rate of incident cognitive impairment.9 Considering five out of six patients 
with atrial fibrillation are at least 65 years of age,13 improving atrial fibrillation 
management among older adults is imperative to reduce the burden of ischemic stroke. 
This introduction reviews information regarding the use of anticoagulants in 
nursing homes. We then review the importance of nursing homes as a segment of the 
healthcare industry. A summary of the evidence on anticoagulants is also provided. We 
then provide a review of what is known about anticoagulant use in nursing home settings. 





coined because the understudied population of nursing home residents are most likely to 
be in need of supportive clinical evidence regarding anticoagulation, but least likely to have 
risk/benefit information from trials. This introduction highlights research gaps regarding 
the contemporary use of anticoagulants in nursing home residents. 
Nursing homes: an important segment in the healthcare industry 
The United States, like so many countries, is experiencing a “silver tsunami” 
owing to the aging of the population. By 2060, it is estimated that almost 1 in 4 
Americans will be at least 65 years of age (currently 15%).14,15 During this time period, 
the number of Americans over 85 years of age is expected to triple to ~19.7 million, 
representing 4.7% of the total United States population (2.0% currently).14 Given these 
shifts in the age distribution, the need for nursing home care is likely to increase. By 2040 
nursing homes are expected to provide care for 7.3 million patients annually.16  
Currently, in the United States, on any given day ~1.4 million residents live in 
one of the ~16,000 nursing homes.17 By 2050, the demand for long-term care services is 
projected to nearly double. Among people aged at least 85 years, nursing home care 
accounts for the largest share of healthcare expenditures.18 This is because people in this 
age group often have a high disability rate and need help in activities of daily living.19,20 
In the United States, Medicaid21 bears the brunt of most nursing home costs (e.g., $60 
billion in 2016).22 With a staggering $92,000 median annual per-resident nursing home 
cost coupled with annual expenditure growth rates at 3.5%,23 reducing acute and post-
acute care expenditures, while striving for improved outcomes with pharmacotherapy, is 





advanced age, virtually all nursing home residents with atrial fibrillation have indications 
for anticoagulation (CHA2DS2-VASc score >2).
24 Given the severity of cognitive and/or 
functional deficits of nursing home residents, the net clinical benefit of anticoagulation is 
often less certain compared with independent community dwelling older adults. 
Changing landscape of anticoagulant use  
There has been a dramatic change in the landscape of anticoagulation in the past 8 
years. Until 2010, vitamin K antagonists were the only marketed oral anticoagulants (i.e., 
only warfarin in the US). Meta-analysis of clinical trials supports a 64% risk reduction for 
stroke and a 0.3% increased risk for serious extracranial hemorrhage with warfarin versus 
placebo in patients with atrial fibrillation.25 Anticoagulation is recommended for high risk 
patients (CHADS2 or CHA2DS2-VASc >2) with atrial fibrillation,
24 but for warfarin users, 
concerns remain regarding time spent outside the therapeutic range. In 9 of 15 trials, the 
time in therapeutic range for warfarin was >65%.26 Yet, in the “real world”, treated 
patients26 including nursing home residents27 spent ~50% of time outside the therapeutic 
range, placing them at risk for adverse events.26  
Alternatives to warfarin— direct acting oral anticoagulants (DOACs)— have 
entered the market since 2010. In the United States, dabigatran was the first to be approved 
by the Food and Drug Administration in the fall of 2010, followed by rivaroxaban (2011), 
apixaban (2012), and edoxaban (2015). These 4 medications were approved for patients 
with atrial fibrillation based upon head to head Phase III clinical trial comparisons versus 
warfarin.28–31 Reviews of the trial and post-marketing observational evidence have 





with a potentially lower risk of intracranial hemorrhage.32,33 Yet, clinicians caring for 
nursing home residents may be hesitant to extrapolate trial evidence to their patients. 
Unlike warfarin, the direct acting agents do not typically require strict monitoring.34–37 For 
these reasons, it comes as no surprise that direct acting oral anticoagulant use rose rapidly 
in the United States,38,39 initially displacing warfarin38 and subsequently expanding the 
number of treated community dwelling atrial fibrillation patients.40  
Before the widespread availability of the DOACs, low treatment rates were 
common in the United States and internationally.40-43 In two large community based 
cohorts (enrolled 1996-97 and 2006-09) of high-risk older adults with atrial fibrillation, 
over 40% of patients hospitalized for ischemic stroke were discharged without an oral 
anticoagulant.41 In Sweden, 73% of adults with atrial fibrillation 80 years and older were 
discharged without an oral anticoagulant after an ischemic stroke between 2006-2013.42 In 
a large single-center cohort in France, hospitalized patients with atrial fibrillation over 75 
years of age were untreated with oral anticoagulants in 59% of hospital stays between 
2009-2013.43 However, evidence suggests that the community dwelling Medicare 
Advantage population had a high (70%) prevalence of oral anticoagulant use for atrial 
fibrillation (although the study’s methods may have inflated this estimate), which remained 
relatively stable over the period 2008-2014.44 
In the general United States population, the prevalence of oral anticoagulant use at 
ambulatory care visits by patients with a diagnosis of atrial fibrillation increased from 52% 
to 67% over the period 2009 to 2014, and the number of visits with warfarin use was similar 





Belgium45 and Germany46 have reported increased use of anticoagulants comparing periods 
after to before the availability of the DOACs. In a community based registry of US patients 
with newly diagnosed atrial fibrillation initiating oral anticoagulation between 2013-2016, 
75% of patients initiated DOACs (40% rivaroxaban, 30% apixaban, and 6% dabigatran) 
while 25% initiated warfarin.39 More than 70% of adults over age 75 years in this 
community based cohort initiated DOACs in this study.39 Similar distributions of prevalent 
DOAC (80%) versus warfarin use (20%) were observed among commercially insured and 
Medicare Advantage members overall and among older adults as of the first quarter of 
2017.47 In the setting of secondary prevention for patients with atrial fibrillation discharged 
from Get With the Guidelines Stroke hospitals after an ischemic stroke, almost all (88%) 
patients were discharged on an oral anticoagulant, but only 18% were discharged on a 
DOAC as of 2012.38  
Use of anticoagulants in nursing homes   
Most nursing home residents with atrial fibrillation are high risk and qualify for 
anticoagulation.48,49 Yet, historically, fewer than half of nursing home residents with 
atrial fibrillation were treated48,49 owing to high perceived bleeding risk,41,50 labile 
anticoagulation with warfarin in nursing homes (~50% of time outside of therapeutic 
range),27,51,52 and a high burden of complicating clinical factors (i.e., polypharmacy, 
comorbidities, cognitive impairment, functional limitations).17,53,54 Only one-third of 
residents newly initiating warfarin for atrial fibrillation remain on treatment at 1-year, 
suggesting improvements are needed in pharmacologic management of these patients.55 





nursing homes were regional in scope, and were based on data before direct acting oral 
anticoagulants were approved by the Food and Drug Administration.27, 48-52,55-57  
The uptake of DOACs in nursing homes remains unknown. It is likely that the 
diffusion of DOACs to nursing home residents may be slower than in the community 
(which may be appropriate owing to the absence of evidence in a clinically complex 
population). There is a paucity of information regarding the safety and effectiveness of 
warfarin and DOACs in the oldest old, complicating the selection of a specific 
medication.58 The Birmingham Atrial Fibrillation Treatment of the Aged randomized 
clinical trial comparing warfarin to aspirin in community dwelling patients over 75 years 
of age constitutes the strongest evidence in support of the anticoagulation of older 
adults.59 The study reported a ~50% reduction in the rate of stroke and a comparable 
bleeding risk in those randomized to warfarin,59 however the time in therapeutic range 
was higher (67%) than is typical in nursing home residents. Even with the availability of 
direct acting oral anticoagulants, appropriately managed warfarin in older adults is 
expected to be the preferred regimen for certain patients, especially where frequent 
monitoring is viewed as beneficial. Beyond the decision to initiate anticoagulation, the 
question of if and when to discontinue therapy in the context of changes in a resident’s 
clinical and functional status is also important. In Veterans at least 65 years of age treated 
with warfarin for atrial fibrillation, 16% continued anticoagulation after an incident 
dementia diagnosis and the rates of stroke and death were lower (with no excess rates of 






In the nursing home setting, concern about safe use of warfarin is warranted. 
Gurwitz et al documented that adverse events associated with warfarin therapy are 
common in the nursing home setting.27 The authors noted that most of the warfarin-
related adverse events were preventable with appropriate warfarin management at the 
prescribing and monitoring stages.27 Recent research has cautioned that practical advice 
on handling of warfarin treatment and drug interactions is needed because electronic 
alerts embedded within electronic medical records appeared to be insufficient to change 
practice.61 
Contemporary evidence for the treatment of atrial fibrillation is lacking in nursing 
homes. The frequency of warfarin use and the quality of monitoring may have changed 
since earlier evaluations were conducted. The availability of DOACs requiring less 
monitoring and having less potential for interactions may have increased the number of 
residents receiving oral anticoagulants. Moreover, shifts in anticoagulant utilization 
precipitated by the emergence of the direct acting agents may have improved outcomes for 
residents with atrial fibrillation. 
Evidence from clinical trials should not be extrapolated to nursing home residents 
Evidence on the safety and effectiveness of the direct acting oral anticoagulants 
specific to nursing home residents is needed. Decision-making in nursing homes is often 
complicated by the presence of cognitive impairment and functional limitations. Whether 
benefits of anticoagulation outweigh harms among residents with severe cognitive 
impairment and physical limitations is unknown. Advanced age, comorbid diseases, and 





maintenance of warfarin within a narrow therapeutic range is challenging in nursing homes. 
Nursing home residents have been excluded from recent evaluations of anticoagulation 
practices38,39 and have not been identified in recently published trials.28–31  
The 2016 Joint Scientific Statement from the American Heart Association, 
American College of Cardiology, and American Geriatrics Society62 called for atrial 
fibrillation research on anticoagulant comparative effectiveness, adverse event risks by 
specific anticoagulant, consequences of non-adherence, and cessation of anticoagulation in 
older adults. One in three nursing home residents with atrial fibrillation have a history of 
stroke, placing them at increased risk of recurrent stroke.52 Yet as few as 30% of nursing 
home residents with atrial fibrillation received anticoagulation historically.48,49,51 
Evidence to inform anticoagulant treatment decisions among the ~240,000 
American nursing home residents with atrial fibrillation is needed.17,52 Clinical trials of 
direct acting oral anticoagulants will not likely be conducted in nursing homes despite the 
evidence needed to inform the difficult treatment decisions facing residents and their 
providers. In the absence of the “gold-standard” study design, observational research using 
large databases of real-world patients is well-suited to handle treatment effect 
heterogeneity and to inform decisions made for an individual patient. Evidence on key 
parameters (e.g., use, dosing, safety, effectiveness) of direct acting oral anticoagulants and 
contemporary evidence on warfarin specific to the nursing home setting are needed to 
identify changes in anticoagulant use patterns, to quantify their impact, and to improve 





The quality of medication decisions in the nursing home environment depends upon 
the quality of communication between on-site clinicians (e.g., nurses, nurse practitioners), 
off-site physicians, consultant pharmacists, social workers, the patient and their family.64,65 
This introduction highlights the need for evidence to inform a shared decision-making 
process and address the dilemma facing all clinicians caring for very old, clinically 
complex patients: Will initiating an anticoagulant cause harm without the potential for 
substantial benefit? Is withholding an anticoagulant (proven effective in younger, less frail 
patients) more judicious? Will this resident benefit from aggressive pharmacologic 
management of atrial fibrillation? If so, which specific anticoagulant will increase the 
probability of benefit while reducing risk? The time has come to address the information 
needs for a growing segment of the population neglected by the evidence. 
Specific Aims 
This dissertation described the diffusion of DOACS, the factors associated with 
anticoagulant use, and evaluated the comparative effectiveness and safety of oral 
anticoagulants in the nursing home population. The specific aims of this dissertation were 
as follows.  
Aim 1. To characterize contemporary and changing vitamin K antagonist and DOAC 
utilization rates in a nursing home population. 
In this aim, the proportion of nursing home residents with atrial fibrillation treated 
with an oral anticoagulant was examined overall, by medication class, by medication and 





Aim 2. To quantify the magnitude of geographic variation in oral anticoagulant use and 
the contributions of resident, facility, and county characteristics to such variation. 
In this aim, county and state level variation in oral anticoagulant use was 
described and multilevel models were fit to quantify the extent to which the variation was 
explained by resident, facility, and county characteristics. 
Aim 3: To compare the incidence of safety (i.e., bleeding) and effectiveness (i.e., ischemic 
stroke) outcomes between vitamin K antagonist users versus DOAC users. 
In this aim, DOAC users (apixaban, dabigatran, and rivaroxaban) were propensity 
matched to warfarin users. The safety and effectiveness of each DOAC was then 
compared to warfarin. 
Data Source and Study Population 
The following datasets (2011-2016) were used for this dissertation: 1.) Minimum 
Data Set (MDS) 3.0 for clinical information (e.g., comorbid diseases, physical and 
cognitive functioning), 2.) Medicare Master Beneficiary Summary File for eligibility and 
mortality, 3.) Medicare Part A for hospitalizations, skilled nursing facility (SNF) stays, 
and diagnoses, 4.) Medicare Part D claims for medications, 5.) the Certification and 
Survey Provider Enhanced Reporting (CASPER) files for nursing facility characteristics, 
and 6.) the Area Health Resource File (AHRF) for county characteristics.  
MDS 3.0 assessments are mandatory for all residents of Medicare- and Medicaid-
certified NHs, including SNFs and long-term care facilities. For long-term care residents, 
assessments are performed at admission, quarterly, annually, and upon a significant 





research quality.65-67 The Master Beneficiary Summary File provides demographic 
information (age, sex, race, ZIP code), vital status (validated Social Security 
Administration date of death), and eligibility for Medicare and Medicaid. Medicare Part 
A claims via the MedPAR Research Identifiable File provided information on hospital 
and SNF claims (e.g., provider IDs, service dates, diagnosis and procedure codes, charges 
and/or Medicare payments). Medicare Part A claims contain International Classification 
of Disease (ICD-9 CM, ICD-10) diagnosis codes and Current Procedural Terminology, 
4th edition codes. Medicare Part D claims document outpatient medication dispensings 
that are reimbursed by Medicare. The Part D Drug Event File contains dates of service, 
payment information, National Drug Codes, quantity dispensed, and days supply. The 
Drug Event File is linked to the Part D characteristics file which provides additional 
information on the brand and generic drug name, the strength, and the dosage form. 
Information on ownership, size, certification, special services, inspection results, facility-
aggregated resident characteristics, and staffing hours derived from annual inspections of 
Medicare- and Medicaid-certified nursing facilities are included in the CASPER files. 
The AHRF is a publicly available database containing county-level data on the 
characteristics of the population (e.g., from the Census), as well as information on the 
supply of healthcare professionals and healthcare facilities in the county (e.g., from the 
American Medical Association Master File and the American Hospital Association 
database).  
 The study population for this dissertation included older non-SNF nursing home 





inclusion criteria were: 1) residence in one of the ~16,000 Medicare- or Medicaid-
certified nursing homes; 2) age >65 years; 3) Medicare fee-for-service Part A and Part D 
beneficiary; 4) 180 days of Medicare fee-for-service Part A and Part D enrollment prior 
to the index date; and 4) a diagnosis of atrial fibrillation. Exclusion criteria were: 1) 
Medicare Advantage member; 2) comatose state at nursing home admission; and 3) SNF 
stay without long-term nursing home residence. Medicare Advantage members are 
excluded due to incomplete Medicare Part A and Part D claims information. The small 
number of residents in a comatose state at admission are also excluded because decision-
making regarding potentially life-extending medications for these patients is distinct from 
the decision-making process for non-comatose patients. Community-dwelling patients 
admitted to a nursing home for a SNF stay that do not remain in or return to the nursing 
home beyond the SNF stay will be excluded because Medicare Part D does not reimburse 
for medications during SNF stays.  
The study period for Aim 1 encompassed 2011 to 2016, and the study population 
included 250,092 residents. The study period for Aim 2 spanned 2014 to 2016, and the 
population for Aim 2 was a subset of those included in Aim 1 with a further inclusion 
requirement of residence in a county with at least 11 included residents. The study 
population for Aim 2 was 89,176 residents. The study population for Aim 3 was distinct 
from Aims 1 and 2 (which included prevalent users and non-users). In order to identify 
comparable groups of warfarin and DOAC users, only new users of warfarin or DOACs 
were included. The study population for Aim 3 was 21,346 new-users of warfarin or 






 The primary goal of Aim 1 was to describe anticoagulant utilization patterns in 
nursing homes over time. Using a repeated cross-sectional design, we sought to estimate 
the proportion of residents known to be residing in a nursing home on a specific day that 
were receiving oral anticoagulants for atrial fibrillation. We examined prevalence 
because it reflects the current treatment for all United States nursing home residents with 
a diagnosis of atrial fibrillation, rather than only the subset who were newly initiating 
during a given time window. Furthermore, the decision to initiate may not be the most 
relevant decision for many residents, for whom the decision to discontinue, change 
dosages, or switch anticoagulants may be most important. For this reason, we examined 
dosing, switching, and discontinuation of oral anticoagulants, in addition to point 
prevalence. Each of these measures were defined using information on Part D claims 
(dispensing dates and days supply), adjusting for early refills and inpatient 
hospitalizations as needed and allowing for a grace period between fills. In addition to 
describing utilization patterns, nursing home resident characteristics were also described 
by anticoagulation status (i.e., treated and untreated) and by type of oral anticoagulant 
(vitamin K antagonist and DOAC) in both 2011 and 2016 (to describe changes in groups 
over time). 
In Aim 2, data were aggregated to the county and state levels to describe variation 
in use across nursing homes and geographies. We used multilevel modeling as our data 
were inherently nested (residents within counties within states). We could not examine 





evaluated the explanatory power of facility characteristics as fixed effects in multilevel 
models. Specifically, to evaluate the extent to which resident characteristics, facility 
characteristics, county characteristics, and state of residence explained variation in oral 
anticoagulant use among nursing home residents with atrial fibrillation, we fit a series of 
five multilevel models:  
Model 1. Null two-level logistic model including a random intercept term for county 
level variation: 
logit (𝑃(𝑌𝑖𝑗𝑠 = 1|𝑏0𝑗)) =  𝛽0 + 𝑏0𝑗 + 𝜷𝒕 
The outcome (𝑌𝑖𝑗𝑠) equaled 1 if resident i within county j in state 𝑠 was exposed to an 
oral anticoagulant on the point prevalence date, and otherwise the outcome equaled 0; 𝛽0 
is the average log-odds of the proportion of exposed residents given the same level 
county effects, while 𝑏0𝑗 is the county specific random intercept measuring variation in 
the proportion of residents exposed to oral anticoagulants on the log-odds scale, and 𝜷𝒕 
was a fixed effect for time (year). The variance in intercepts across counties is assumed to 
be normal with mean 0 and variance 𝜎𝑐
2. 
Model 2. A hierarchical two-level logistic model including random intercepts for 
counties and resident characteristics: 
logit (𝑃(𝑌𝑖𝑗𝑠 = 1|𝑏0𝑗 , 𝑿𝑖𝑗𝑠
𝑟 )) = 𝛽0 + 𝑏0𝑗 + 𝜷𝒓𝑿𝑖𝑗𝑠
𝒓 +  𝜷𝒕 
Model 2 additionally includes 𝜷𝒓𝑿𝑖𝑗𝑠
𝒓 , terms for a vector of resident characteristics 
included as fixed effects. The between-county variance estimate from this model is 





Model 3. A hierarchical two-level logistic model including random intercepts for 
counties and adjusting for resident and facility level characteristics: 
logit (𝑃(𝑌𝑖𝑗𝑠 = 1|𝑏0𝑗 , 𝑿𝑖𝑗𝑠
𝑟 , 𝑿𝑖𝑗𝑠
𝑓






Model 3 also includes 𝜷𝒇𝑿𝑖𝑗𝑠
𝑓
 (terms for a vector of facility characteristics included as 
fixed effects). The between-county variance estimate from this model is adjusted for both 
resident and facility characteristics. 
Model 4. A hierarchical two-level logistic model including random intercepts of counties 
and adjusting for resident, facility, and county level characteristics: 
logit (𝑃(𝑌𝑖𝑗𝑠 = 1|𝑏0𝑗, 𝑿𝑖𝑗𝑠
𝑟 , 𝑿𝑖𝑗𝑠
𝑓










𝑐  represents terms for a vector of county characteristics included as fixed 
effects. The between-county variance estimate from this model is adjusted for resident, 
facility, and county characteristics. 
Model 5. A hierarchical three-level logistic model including a random intercept term for 
county level variation, a second random intercept term for state level variation, and 
adjusting for resident, facility, and county level characteristics: 














This model includes random intercepts of states variation in anticoagulant use, 𝑏0𝑠 The 
between-county variance estimate from this model is adjusted for resident, facility, and 





In addition to the five multilevel models, we also fit a single level logistic model with 
only resident characteristics and time to examine differences between each county’s 
observed prevalence of anticoagulant use and the prevalence that would be expected 
based solely on the composition of its resident population (i.e., observed versus 
predicted). 
Comparative Safety and Effectiveness 
 Observational pharmacoepidemiologic studies comparing outcomes of alternative 
treatment strategies must inevitably consider and address threats to internal validity from 
selection bias (e.g., confounding by indication), information bias (e.g., exposure and 
outcome misclassification), and confounding. Although observational studies generally 
cannot achieve the level of causal inference derived from clinical trials, the application of 
modern pharmacoepidemiologic methods can be applied to produce observational 
comparative effectiveness evidence that is valuable for informing clinical practice, 
particularly for populations for whom clinical trial evidence is sparse and unlikely to be 
generalizable. Therefore, in Aim 3, we implemented an active comparator new-user 
cohort design to mitigate confounding by indication.68 Furthermore, we used validated 
outcome definitions to attenuate concerns of misclassification, and we applied propensity 
score matching to assemble balanced groups of warfarin and DOAC users. The 
propensity score estimates the probability of receiving a treatment using logistic 
regression, and once estimated is used to assemble groups with similar characteristics.63,64 





the outcome, we applied an as-treated design and censored residents discontinuing or 
switching anticoagulants. 
 In recognition of the unique pharmacologic profiles of individual DOACs,34-37 
separate propensity matched comparisons were implemented for apixaban, dabigatran, 
and rivaroxaban versus warfarin. Due to a high prevalence of DOAC dosing that was not 
aligned with Food and Drug Administration (FDA) approved labeling, and earlier 
evidence suggesting misaligned dosing is associated with risk for adverse events, we 
performed analyses among subgroups defined by DOAC alignment or misalignment with 
labeled dosing recommendations. Separate competing risk Cox proportional hazards 
models were fit for effectiveness (i.e., ischemic stroke and transient ischemic attack 
(TIA)), safety (intracranial and extracranial bleeding), other ischemic events (i.e., 
systemic embolism, venous thromboembolism (VTE), acute myocardial infarction 
(AMI)), and all-cause mortality. To better understand the overall risk-benefit profile of 
each medication, a net clinical benefit composite outcome which included each of these 







CHANGES IN ANTICOAGULANT UTILIZATION AMONG UNITED STATES 









Nursing home residents with atrial fibrillation (AF) are at high risk for ischemic stroke 
and bleeding events. The most recent national estimate (2004) indicated less than one-
third of this high-risk population was anticoagulated. Whether direct-acting oral 
anticoagulant (DOAC) use has disseminated into nursing homes and increased 
anticoagulant use is unknown. 
Methods 
A repeated cross-sectional design was used to estimate the point prevalence of oral 
anticoagulant use on July 1st and December 31st of calendar years 2011-2016 among 
Medicare fee-for-service beneficiaries with AF residing in long-stay nursing homes. 
Nursing home residence was determined using Minimum Data Set 3.0 records. Medicare 
Part D claims for apixaban, dabigatran, edoxaban, rivaroxaban, and warfarin were 
identified and point prevalence was estimated by determining if the supply from the most 
recent dispensing covered each point prevalence date. A Cochran-Armitage test was 
performed for linear trend in prevalence. 
Results 
On December 31, 2011, 42.3% of 33,959 residents (median age: 85; Q1 79, Q3 90) were 
treated with an oral anticoagulant, of whom 8.6% used DOACs. The proportion receiving 
treatment increased to 47.8% of 37,787 residents as of December 31, 2016 (p<0.01); 
48.2% of 18,054 treated residents received DOACs. Demographic and clinical 





8,734 DOAC users received standard dosages and most were treated with apixaban 
(54.4%) or rivaroxaban (35.8%) in 2016.  
Conclusions 
Increases in anticoagulant use among US nursing home residents with AF coincided with 








The number of Americans with atrial fibrillation (AF) is projected to double to 
more than 12 million between 2010 and 2050, driven by increasing population size, 
aging, and a rising burden of risk factors such as obesity.4 By 2050, more than half of 
Americans with AF are expected to be over 80 years of age.13 As of 2010, approximately 
one in eight Americans over the age of 85 resided in an institutional setting.65 
Anticoagulation decisions for older adults with AF at high risk for ischemic stroke 
are particularly challenging because most are also at high risk of bleeding. This leaves 
providers uncertain of the net benefit of treatment41,50 and has contributed to low use of 
anticoagulants for high-risk older adults72 despite evidence supporting their safety and 
effectiveness for older populations.59 Nursing home residents with AF are at particularly 
high risk for ischemic stroke and bleeding events due to a high prevalence of risk factors, 
including frailty, advanced age, and comorbidities.48-49, 73 Yet in the final wave of the 
National Nursing Home Study conducted in 2004, less than one-third of this high-risk 
population was anticoagulated.49 Historically, nursing home residents commonly 
experienced high rates of adverse events related to warfarin therapy, many of which were 
considered preventable and associated with time spent outside of the therapeutic range.27  
Among patients in the United States attending ambulatory care visits, the market 
entrance of direct-acting oral anticoagulants (DOACs) was followed by a shift in 
utilization from warfarin to DOACs, accompanied by an increase in the fraction of 
patients with AF receiving anticoagulation.40 This shift extends to high-risk community 





during the period 2013-2016 were prescribed DOACs.39 Nursing home residents have a 
high burden of cognitive impairment and shortened life expectancy,74-75 which demands a 
complex multi-stakeholder shared decision-making process. Furthermore, extensive 
functional limitations17 diminish residents’ access to specialists outside of the 
institutional setting who have a greater propensity to prescribe anticoagulants overall and 
DOACs specifically.76,77 It is uncertain the extent to which the use of DOACs has 
disseminated into the nursing home setting and increased anticoagulant use for this high-
risk and vulnerable population. 
Methods 
Data 
Medicare administrative files and the Minimum Data Set (MDS) 3.0 were linked 
to assemble a near-comprehensive data source encompassing enrollment and 
demographic characteristics from the Medicare Beneficiary Summary file, hospital and 
SNF claims (Medicare Part A), prescription claims (Medicare Part D), and clinical and 
functional assessment data (MDS 3.0). The MDS 3.0 is mandatory for all Medicare and 
Medicaid certified nursing facilities and the information collected through the MDS 3.0 
has been previously validated.65-67 Medicare administrative files and the MDS 3.0 were 
used through a data use agreement with the Centers for Medicare and Medicaid Services 
(CMS). Dr. Alcusky had full access to all study data and takes responsibility for data 
integrity and analysis. Due to the sensitive nature of the CMS research identifiable files, 
researchers interested in requesting files should consult the information available from 





Institutional Review Board approved this study (H00015376); informed consent was not 
required. 
Study Design 
A repeated cross-sectional design was used to estimate the point prevalence of 
oral anticoagulant use overall, by anticoagulant class (i.e., warfarin or DOAC), and by 
specific medication on July 1st and December 31st of calendar years 2011-2016. A 12-
month lookback period was used for all cross-sections with the exception of the first 
because Medicare and MDS 3.0 data were only available for 6 months and 9 months, 
respectively, prior to July 1, 2011. 
Study Population 
For each cross-section, Medicare fee-for-service beneficiaries with diagnosed AF 
residing in a long-stay nursing home on the point prevalence date and with at least six 
months of baseline Medicare enrollment were eligible to enter the study population. 
Included residents had at least one diagnosis of AF or flutter (Table 2.1) on a Medicare 
Part A claim and one diagnosis of AF, atrial flutter, or dysrhythmia on a MDS 3.0 
assessment in the 12 months preceding the point prevalence date. Excluded residents 
were <65 years of age, without at least one Part D claim in the preceding 12 months, 
enrolled in hospice, or in a comatose state. 
Anticoagulant Use 
Oral anticoagulant use including apixaban, dabigatran, edoxaban, rivaroxaban, or 
warfarin was measured using a daily approach, enabling a precise estimate of current 





a nursing home on a specific date. The point prevalence of oral anticoagulant utilization 
was estimated on the first day of each half-year of the study (July 1st and December 31st 
of calendar years 2011-2016) by summing the number of eligible residents exposed to an 
anticoagulant on that date and dividing by the number of residents in the population. 
Exposure was estimated using fill dates and number of days supplied from Part D claims 
in the 12-months preceding the point prevalence date. Each day a resident was present in 
the study population was marked as exposed if the supply from the most recent 
dispensing was sufficient to cover that day, accounting for medication accumulation and 
inpatient/SNF stays. Residents with at least one dispensing for an oral anticoagulant who 
were not exposed on the point prevalence date were considered to have discontinued 
anticoagulant use. For analyses of switching at the level of the class (warfarin or DOAC), 
residents that made multiple switches during a cross-section were grouped according to 
the most recent switch. Among switchers, the proportion switching from one class to the 
other and back was also described. 
Resident Characteristics 
Resident characteristics were operationalized using information from the most 
recent long-stay MDS 3.0 assessment preceding the point prevalence date, diagnoses on 
Part A claims and medication information on Part D claims during the 12-months 
preceding the point prevalence date. Resident characteristics included demographics, 
hospital admissions (including for ischemic stroke,79 extracranial bleeding,80 or 
intracranial hemorrhage80), CHA2DS2-VASc risk score,
81 ATRIA risk score,82 select 





CHA2ADS2-Vasc score) or bleeding risk
83 (fall history, chronic renal insufficiency84), 
select medication classes and total unique medications (as an indicator of polypharmacy) 
used, functional status, and cognitive impairment. Renal functioning was grouped in four 
categories using a combination of information from Medicare claims and MDS 3.0 items: 
1) on dialysis (MDS item O0100J2), 2) end-stage renal disease (MDS item I1500) and 
not on dialysis, 3) chronic renal insufficiency (corresponding to an estimated glomerular 
filtration rate <60 ml/min)84 without end-stage renal disease or dialysis, and 4) no 
evidence of chronic renal impairment. The select medication classes described were those 
associated with increased bleeding risk (non-steroidal anti-inflammatory drugs, 
antiplatelets) and chronic medications (statins, angiotensin converting enzyme inhibitors, 
angiotensin receptor blockers) used for the prevention of cardiovascular and 
cerebrovascular events. Use of selective serotonin reuptake inhibitors was also described 
due to a possible association with bleeding when combined with anticoagulant use.85,86 A 
recent history of one or more falls since nursing home admission or the last assessment 
was ascertained from the MDS 3.0 (item J1800) and operationalized dichotomously. 
Functional status was operationalized as the four-item activities of daily living (ADL) 
score, which summarizes a resident’s ability to perform four ADLs (personal hygiene, 
toileting, locomotion, and eating) and ranges from a score of 0 (independent in all four 
ADLs) to 16 (totally dependent in all four ADLs).87 Cognitive impairment was scored 






Characteristics of the study population were described overall and by 
anticoagulant use for the residents included in the December 31st 2011 and 2016 point 
prevalence estimates. Among residents using oral anticoagulants as of December 31st 
2011 and 2016, resident characteristics were summarized separately for users of DOACs 
and warfarin. Descriptive statistics included frequencies and percentages for categorical 
variables and medians with first and third quartiles for continuous variables.  
The prevalence of anticoagulant use was plotted overall and by anticoagulant 
class for the twelve half-years comprising the study period. For each half-year, the 
prevalence of anticoagulant use was also described by specific medication. The 
prevalence of anticoagulant use overall and by medication class was also described 
within subgroups defined by renal function, cognition, and functional status for the 
December 31st 2011 and 2016 cross-sections. The prevalence of anticoagulant 
discontinuation and the prevalence of switching between medication classes were each 
plotted over the course of the study period. A Cochran-Armitage test with a 2-sided 
statistical significance level of <0.05 was performed for linear trend in prevalence of 
anticoagulant use. Data analyses were performed with SAS Version 9.4 (SAS Institute 
Inc.) and Microsoft Excel 2016 (Microsoft Corporation). 
Results 
Resident Characteristics 
The number of residents included ranged from 17,895 for the July 1, 2011 cross-
section to 37,787 for the December 31, 2016 cross-section. Resident age remained 





90). In 2016, 34% of residents were men; with 29% men in 2011. The proportion of 
residents with CHA2DS2-Vasc scores >6 was 36% in 2011 and 30% in 2016; in each time 
period >99% of residents had scores of >2. The fraction with renal impairment (chronic 
renal insufficiency, end-stage renal disease, or using dialysis) was 51% in 2016 and 43% 
in 2011. Residents were substantially limited in ADLs in 2011 and 2016. The prevalence 
of moderate to severe cognitive impairment was 39% in 2011 and 34% in 2016. The 
median number of unique prescriptions among residents in 2011 was 17 and in 2016 was 
18. 
Table 2.2 displays characteristics of the resident population in 2011 and 2016 for 
both treated and untreated residents. In 2011 and 2016, the median CHA2DS2-Vasc score 
was 5 (Q1 4, Q3 6) and the median ATRIA risk score was 3 (Q1 3, Q3 6) among both 
treated and untreated residents. In 2011, moderate to severe cognitive impairment was 
present among 44% of untreated and 34% of treated residents, while in 2016 the 
prevalence was 40% and 30%, respectively. During the 2011 and 2016 cross-sections, 
5% of untreated and 7% of treated residents had been hospitalized for ischemic stroke. 
Among untreated residents, 23% used antiplatelets in 2011 and 19% used antiplatelets in 
2016; less than 10% of treated residents used antiplatelet medication during either time 
period. Table 2.3 displays characteristics of nursing home residents treated with DOACs 
and warfarin in 2011 and 2016. 
Anticoagulant Use 
The proportion of residents with AF treated with oral anticoagulants was 42.4% 





Anticoagulant use remained stable through the close of 2013, at which time 42.8% of 
residents were treated, 35.2% with warfarin and 7.7% with DOACs (Figure 2.1). 
Beginning in the first half of 2014 the prevalence of anticoagulant use increased during 
each half-year through the end of the study (December 31st, 2016), at which time 47.8% 
of residents were treated (p-value for 2011-2016 trend <0.001). This period (2014-2016) 
of increasing anticoagulant use coincided with a decline in warfarin use and a rise in 
DOAC use such that by the end of 2016, the prevalence of warfarin use (24.7%) was 
nearly equal to DOAC use (23.1%).  
Dabigatran use increased during the early study period and peaked in the first half 
of 2012 before stabilizing in the range of 2.2%-3.1% through 2016 (Table 2.4). In 
contrast, the prevalence of rivaroxaban and apixaban use continued to rise through the 
end of the study. Over the five full years (2012-2016) after market entry, rivaroxaban use 
increased from 0.4% to 8.3%. During the four full years after market entry (2013-2016), 
apixaban use grew from 0.1% to 12.6%. In contrast, edoxaban use remained rare after its 
approval in 2015.  
In 2011, 36% of residents with moderate-to-severe cognitive impairment were 
treated with oral anticoagulants and 46.4% of cognitively intact or mildly impaired 
residents were treated (Table 2.5); the percentages treated in 2016 were 40.4% and 
51.7%, respectively. The change in the prevalence of oral anticoagulant use between 
2011 and 2016 was 5% among residents with and without chronic renal insufficiency 
(43% to 48%); the change among those with end-stage renal disease was 8% (39% to 





without a diagnosis of renal impairment, while standard DOAC doses were commonly 
used among those with chronic renal insufficiency (47%), end-stage renal disease (40%), 
and those on dialysis (31%). Among 2,676 apixaban users likely to have an indication for 
dosage reduction (at least two of: weight <60 kilograms, renal impairment, age >80 
years), 26.2% received the standard dose. Among 3,122 apixaban users who likely did 
not have an indication for dose reduction, 36.0% received the low dose. As of the second 
half of 2016, 48.3% of white residents, 46.5% of black residents, 42.3% of Hispanic 
residents, and 36.7% of Asian/Pacific Islander residents were treated with oral 
anticoagulants (Table 2.7). No sex-based differences in anticoagulant use were observed. 
Anticoagulant Switching and Discontinuation 
The proportion of nursing home residents with AF discontinuing oral 
anticoagulants was in the range of 8.6% to 10.1% for each half-year of the study period 
(Figure 2.1). Among treated residents, the fraction switching from a DOAC to warfarin 
remained in a narrow range (1.8%-2.4%) from the second half of 2011 through the end of 
2016 (Figure 2.2). Switchers from warfarin to a DOAC comprised 2.4% of treated 
residents in the first half of 2011 and 7.8% of treated residents in the second half of 2016. 
Among residents that switched between anticoagulant classes, the percentage of 
switchers that switched back to their original anticoagulant class ranged from 13% to 
21% of all switchers during 2011 and 2012, and from 8% to 11% of all switchers during 






The proportion of US nursing home residents with AF using oral anticoagulants 
was stable during the initial three-year period following the market release of the DOACs 
in the US, but then steadily increased from 2014 to 2016. Underlying this overall trend, 
the pace of gradual decline in warfarin use mirrored uptake in DOAC use during 2011-
2013, with DOAC uptake consistently outpacing declines in warfarin use beginning in 
2014. Utilization growth peaked for dabigatran in 2012 and slowed for rivaroxaban in 
2015. Continued increases in DOAC use and anticoagulation overall were fueled by the 
rapid uptake of apixaban, which began approximately one year after its market entrance 
(2014) and was sustained through the end of 2016. By the end of 2016, approximately 
equal fractions of residents were treated with DOACs as were treated with warfarin.  
Prior to DOAC availability, low use of oral anticoagulants among high-risk older 
adults with AF was reported in the US and internationally.42,43,72,88,89 In two large US 
community-based AF cohorts (median CHA2DS2-Vasc: 5), over 40% of patients 
hospitalized for ischemic stroke were discharged without an anticoagulant.41 Estimates of 
anticoagulant use among US nursing home residents with AF in the 1990s and early 
2000s suggested approximately two-thirds of residents were not treated with warfarin.49,52 
At that time, reports of high rates of adverse events and labile international normalized 
ratios for nursing home residents27,52 were accompanied by physician uncertainty 
regarding the relative benefits and risks of warfarin in the long-term care setting.50 This 
uncertainty regarding the net benefit of treatment continues to affect anticoagulant 





Low use of anticoagulation was widespread despite evidence supporting clinical 
benefit. A meta-analysis of clinical trials comparing warfarin to control reported a 64% 
risk reduction for stroke and comparable risk for major extracranial hemorrhage in 
patients with AF.25 Similar findings were reported for warfarin versus aspirin among 
older adults over 75 years.59 Prominent reasons clinicians refrain from anticoagulation 
among high-risk older adults post-stroke include perceived fall risk, poor prognosis, and a 
history of bleeding.41,50 Considering a history of falls is common among nursing home 
residents, coupled with a high burden of cognitive impairment74 and short life 
expectancy,75 it is reasonable to expect a lower prevalence of anticoagulation compared 
with community-dwelling populations. Interestingly, although the prevalence of bleeding 
risk factors was directionally consistent with greater provider caution in treating patients 
with higher bleeding risk, more than half of the untreated population had low bleeding 
risk (ATRIA<4) and more than three-quarters did not have a recent history of falls. This 
suggests a role for other factors beyond these commonly reported reasons for not 
prescribing oral anticoagulants. In this respect, our findings were similar to earlier studies 
in the nursing home setting which reported lower likelihood of preventative treatment for 
residents with cognitive impairment in addition to atrial fibrillation52 or prior myocardial 
infarction.90 However, existing functional limitations did not appear to deter 
anticoagulant use in our study population, as treated fractions were generally consistent 
across levels of functional limitation.  
Even in the presence of bleeding risk factors, cognitive impairment, and/or 





profile, while incorporating patient and family input. Patients often place greater weight 
on the prevention of stroke than the risk of bleeding,91 which may reflect recognition of 
stroke’s long-term consequences for functioning and cognition.9,11 However, patient 
aversion to bleeding risk as well as the need for additional blood testing and clinical 
evaluation, even with DOACs, may also contribute to lower treatment rates than would 
be expected if guidelines were strictly followed. Beyond the decision to treat, the 
selection of dosage may also be affected by resident factors associated with perceived 
bleeding and stroke risk, potentially leading to dosing that is inconsistent with product 
labeling. In a large US cohort of privately insured and Medicare Advantage enrollees 
with atrial fibrillation, 43% of DOAC users received standard doses in the presence of a 
renal indication for dose reduction while 13% received low doses despite no renal 
indication.92 In the nursing home population, we estimated 44% of DOAC users without 
renal impairment (renal insufficiency, end-stage disease, or on dialysis) received low 
dosages and 44% with renal impairment received standard dosages. In the community 
dwelling population, overdosing was associated with a more than two-fold increased risk 
of bleeding and comparable stroke risk, while under dosing was associated with a more 
than four-fold higher stroke risk among apixaban (but not rivaroxaban or dabigatran) 
users.92  
After DOACs became available, changes in anticoagulant utilization among US 
nursing home residents were delayed and smaller in magnitude compared with changes in 
the broader community-dwelling population. The prevalence of anticoagulant use among 





start of our study (2011). In the early period of DOAC availability, the percentage of 
residents anticoagulated remained steady before increasing to 48% during 2014-2016. 
This contrasts with the ambulatory care population, where the percentage of office-based 
visits for AF with anticoagulant use increased from 52% in 2009 to 67% by the end of 
2014.40 The rate of diffusion of DOACs in the community was also faster than in the 
nursing home, as the number of office visits for AF with DOAC use equaled the number 
of visits with warfarin use by the close of 2013.40 The proportion of nursing home 
residents using DOACs did not approach the proportion using warfarin until the end of 
2016. However, increases in anticoagulant and DOAC use continued through the end of 
our study, suggesting these trends may have continued into 2017. The uptake of DOACs 
among Medicare Supplemental enrollees in the community was slower than the broader 
community-dwelling population and more closely resembled uptake among nursing home 
residents.44  
Clinical trial evidence comparing DOACs to warfarin specific to older adults is 
limited. Meta-analysis of available trial data has suggested the DOACs have similar or 
improved efficacy and comparable or lower risk of major bleeding (except for 
dabigatran) compared with warfarin in adults 75 years and older.93,94 Although time in 
therapeutic range was below target levels in the DOAC trials (55%-65%),94 similar to 
studies of real-world populations,26 inferences regarding comparative effectiveness 
among older adults maintained within warfarin’s therapeutic range require additional 
evidence. In the absence of definitive evidence in older frail populations, and in light of 





in anticoagulant use during 2014-2016 may have been driven by several factors. 
American College of Cardiology/American Heart Association guidelines for AF 
management published in 2014 listed warfarin and DOACs as class one options for non-
valvular AF.24 Lack of monitoring requirements, fewer drug and dietary interactions, and 
less frequent need for dose adjustments may have contributed to subgroups of patients 
receiving treatment with DOACs that historically would not have received warfarin. 
Furthermore, superiority in safety and effectiveness of apixaban versus warfarin in the 
ARISTOTLE trial29 may have tipped the balance of perceived risks and benefits in favor 
of treatment for certain residents, a possibility supported by the timing and magnitude of 
increases in apixaban use.  
Limitations 
In this first national study of anticoagulant use in nursing homes since 2004, we 
employed daily tracking of exposure and repeated point prevalence measurements to 
understand the evolution of anticoagulant use while accounting for switching and 
discontinuation. Limitations stem primarily from the use of diagnostic and medication 
utilization information derived observational data sources. Detailed clinical data on the 
type of AF, AF disease history, and renal functioning were not available. Use of over-the-
counter medications such as aspirin was not observed unless there was a Part D claim. 
Anticoagulant exposure was estimated based on medication fill patterns and actual use 
may have differed, although nonadherence is less of a concern due to the nature of 
medication administration in nursing homes. Finally, this was a population-based study 





medication use over time among US nursing home residents with AF. Although we 
describe resident characteristics in 2011 and 2016, the contributions of within-resident 
correlation and changes in the characteristics of the US nursing home population over 
time to changes in anticoagulant utilization patterns were not evaluated statistically in the 
present study. 
Conclusions 
Even after a marked increase in anticoagulant use between 2004 and 2016, more 
than half of nursing home residents with AF remain untreated. The large majority of 
residents with AF are at high risk for stroke, evidenced by 85% of residents with a 
CHA2DS2-Vasc score of four or more. Recent estimates (2013-2016) of anticoagulant use 
in the community indicate a large majority (75%) of new-users are initiating DOACs, 
including older adults.39 With recent availability of DOAC reversal agents95 and 
emerging observational evidence reinforcing trial findings in real-world populations,96,97 
including the frail,98 it is likely the gradual increase in anticoagulation of nursing home 
residents and ongoing shift from warfarin to DOACs will continue. The early plateau in 
dabigatran use suggests any further increase in DOAC use among nursing home residents 
is likely to be driven by the factor Xa inhibitors apixaban, and to a lesser extent, 
rivaroxaban. Comparative effectiveness research specific to this medically complex older 
adult population is warranted to determine the clinical implications of these shifts in 
anticoagulant prescribing.  
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Figure 2.1 Percentage of US Nursing Home Residents with Atrial Fibrillation 
Treated with Warfarin and Direct Acting Oral Anticoagulants (DOACs), 2011-2016 







Figure 2.2. Percentage of Treated Residents that Switched Between Warfarin and 







Table 2.1 ICD-9 and ICD-10 Code Based Definitions Applied to Medicare Part A 
Claims to Identify Specific Conditions 
Clinical Condition ICD-9 CM Codes* ICD-10 CM Codes* 
Atrial 
fibrillation/flutter† 
42731, 42732 I480, I481, I482, I483, I484, I4891, 
I4892 
Ischemic stroke‡ 43301, 43311, 43321, 
43331, 43381, 43391, 
43401, 43411, 43491, 
436 
I6302, I6312, I6322, I63239, I63232, 
I63231, I63139, I63132, I63131, 
I63039, I63032, I63031, I63011, 
I63012, I63019, I63111, I63112, 
I63119, I63211, I63212, I63219, I6359, 
I6319, I6309, I6329, I6320, I6310, 
I6300, I6330, I63311, I63312, I63319, 
I63321, I63322, I63329, I63331, 
I63332, I63339, I63341, I63342, 
I63349, I6339, I636, I6349, I63449, 
I63442, I63441, I63439, I69432, 
I69431, I63429, I63422, I63421, 
I63419, I63412, I63411, I63430, I6350, 
I63511, I63512, I63519, I63521, 
I63529, I63531, I63532, I63539, 




430, 431, 4320, 4321, 
4329 
I609, I608, I607, I606, I6052, I6051, 
I6050, I604, I6032, I6031, I6030, 
I6022, I6021, I6020, I6012, I6011, 
I6010, I6002, I6001, I6000, I610, I611, 
I612, I613, I614, I615, I616, I618, 




In primary position 
alone: 
5310, 5312, 5314, 
5316, 5320, 5322, 
5324, 5326, 5330, 
5332, 5334, 5336, 
5340, 5342, 5344, 
5346, 53501, 53511, 
53521, 53531, 53541, 
53551, 53561, 53783, 
4560, 45620, 5307, 
53082, 5780, 4552, 
4555, 4558, 56202, 
56203, 56212, 56213, 
In primary position alone: 
K252, K254, K256, K260, K262, 
K264, K266, K270, K272, K274, 
K276, K280, K282, K284, K286, 
K2901, K2931, K2941, K2951, K2961, 
K2921, K2971, K2981, K2991, 
K31811, I8501, I8511, K226, K228, 
K920, K648, K643, K642, K641 K640, 
K5711, K5751, K5753, K5741, K5713, 
K5701, K5791, K5731, K5793, K5781, 
K5733, K5721, K661, K625, K5521, 
K921, K922, N280, R310, R311, R312, 
R319, N898, N920, N921, I312, R58, 





56881, 5693, 56985, 
5781, 5789, 59381, 
5997, 6238, 6262, 
6266, 4230, 4590, 
56881, 7191, 7847, 
7848, 7863 
 
In primary position, 
with above code in 
secondary position: 
5311, 5313, 5315, 
5317, 5319, 5321, 
5323, 5325, 5327, 
5329, 5331, 5333, 
5335, 5337, 5339, 
5341, 5343, 5345, 
5347, 5349, 53500, 
53510, 53520, 53530, 
53540, 53550, 53560, 
455, 56200, 56201, 
56210, 56211, 5301, 
2800, 2851, 2859, 
79092 
M25021, M25022, M25029, M25031, 
M25032, M25039, M25041, M25042, 
M25049, M25051, M25052, M25059, 
M25061, M25062, M25069, M25071, 
M25072, M25073, M25074, M25075, 
M25076, M2508, R040, R041, R042, 
R0481, R0489, R049 
 
In primary position, with above code in 
secondary position: 
K251, K253, K255, K257, K259, 
K261, K263, K265, K267, K269, 
K271, K273, K275, K277, K279, 
K281, K283, K285, K287, K289, 
K2900, K2930, K2960, K2920, K2930, 
K2970, K2980, K640, K641, K642, 
K643, K644, K645, K648, K649, 
K5750, K5710, K5752, K5740, K5712, 
K5700, K5730, K5790, K5792, K5780, 
K5732, K5720, K210, K209, K208, 
K200, D800, D62, D649, R791 
Chronic renal 
insufficiency** 
582, 583, 585, 586, 
587 
M3218, M3214, M3504, N050, N051, 
N052, N053, N054, N055, N056, 
N057, N058, N059, N060, N061, 
N062, N063, N064, N065, N066, 
N067, N068, N069, N070, N071, 
N072, N073, N074, N075, N076, 
N077, N078, N079, N08, N140, N142, 
N144, N150, N158, N159, N171, N16, 
N170, N172, N178, N179, N181, 
N182, N183, N184, N185, N186, 
N189, N19, N261, N269 
*ICD-9 CM code based algorithms were converted to ICD-10 CM codes using the 2016 
General Equivalence Mappings available from the Centers for Medicare and Medicaid 
Services at https://www.cms.gov/Medicare/Coding/ICD10/2016-ICD-10-CM-and-
GEMs.html 
†Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S. A systematic 
review of validated methods for identifying atrial fibrillation using 
administrative data. Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:141-7. 
‡Kumamaru H, Judd SE, Curtis JR, Ramachandran R, Hardy NC, Rhodes JD, Safford 
MM, Kissela BM, Howard G, Jalbert JJ, Brott TG, Setoguchi S. Validity of claims-





racial differences in stroke (REGARDS) study linked with medicare claims. Circ 
Cardiovasc Qual Outcomes. 2014;7:611–9. 
§Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An 
automated database case definition for serious bleeding related to oral anticoagulant use. 
2011;(March):560-566.  
**Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. 
Identification of individuals with CKD from medicare claims data: A validation study. 







Table 2.2 Characteristics of Residents Treated or Not Treated with an 
Anticoagulant, by Time Point 
 December 31, 2011 December 31, 2016 








Demographics     
Age in years, median 
(Q1, Q3) 
86 (80, 91) 84 (78, 89) 86 (79, 91) 83 (77, 89) 
Women, % 70.9 71.2 66.2 65.9 
Hospital admissions in prior 
year, % 
    
Number of hospitalizations, 
% 
    
2-3 38.0 38.4 36.8 37.9 
4+ 13.7 14.1 12.1 13.1 
Ischemic stroke 5.0 7.3 4.7 7.3 
Extracranial bleed 7.9 5.3 7.2 4.5 
Intracranial hemorrhage 1.0 0.4 1.2 0.5 
Unique medications, 
median (Q1, Q3) 
17 (12, 22) 19 (14, 24) 16 (12, 22) 18 (14, 24) 
Select Medications,* %     
NSAID 18.3 15.8 17.7 16.9 
Antiplatelet 22.5 9.5 18.5 8.6 
Statin 42.4 51.0 51.1 60.6 
SSRI 52.3 55.9 50.0 52.0 
ACE inhibitor or ARB 49.8 54.0 45.3 50.1 
Select Comorbidities,† %     
Diabetes 35.2 41.0 36.3 41.8 
Heart failure 42.1 48.7 42.0 48.1 
Hypertension 82.7 84.3 85.7 87.8 
Coronary artery disease 33.4 31.2 31.3 29.3 
Anemia 38.4 32.4 39.2 33.2 
Fall since NH 
admission/last 
assessment 
22.1 18.8 21.8 18.1 
Stroke 19.6 24.3 12.5 16.2 
CHA2DS2-Vasc Risk 
Score, % 
    
2-3 13.6 11.1 15.7 13.0 
4 25.0 22.3 26.9 24.3 
5 27.1 27.3 28.1 29.7 
6 19.4 21.7 18.7 20.3 





ATRIA Bleeding Risk 
Score,  ‡ % 
    
Low (0-3) 54.1 60.8 50.7 55.8 
Intermediate (4)  3.6 4.6 5.8 6.5 
High (5-10) 42.3 34.6 43.6 37.7 
Cognitive skills, %     
Mildly impaired  25.4 26.2 26.1 26.5 
Moderately to 
severely impaired  
44.4 34.2 39.6 29.4 
ADL score (0-16), § 
median (Q1, Q3) 
9 (6, 12) 9 (6, 11) 10 (7, 11) 9 (7, 11) 
*Any Part D claim during the 12-month period 
†Resident characteristics exclude residents with missing values for fall history, heart failure, 
hypertension, diabetes, and stroke (n<10 for all characteristics with missing values in 2011 and 2016). 
‡Percentages may not total 100% due to rounding 
§Higher scores indicate greater limitation in ADLs 
Abbreviations: activities of daily living (ADLs), non-steroidal anti-inflammatory drugs (NSAID), 
selective serotonin reuptake inhibitor (SSRI), angiotensin converting enzyme (ACE), angiotensin 






Table 2.3 Characteristics of Residents using DOACs or Warfarin, by Time Point 
 December 31, 2011 December 31, 2016 








Demographics     
Age in years, median (Q1, Q3) 84 (78, 89) 83 (77, 88) 84 (77, 89) 83 (76, 88) 
Women, % 71.1 71.6 64.6 67.3 
Hospital admissions in prior year, %     
Number of hospitalizations, %     
2-3 38.2 41.0 36.8 39.1 
4+ 13.9 15.7 12.5 13.8 
Ischemic stroke 7.1 10.0 5.9 8.9 
Extracranial bleed 5.0 6.5 5.0 4.0 
Intracranial hemorrhage 0.4 Sup. 0.5 0.5 
Medications     
Unique medications, median (Q1, 
Q3) 
19 (14, 24) 20 (15, 26) 
18 (14, 23) 19 (14, 24) 




Select medications, * %     
NSAID 15.6 17.9 15.1 18.7 
Antiplatelet 9.2 13.8 7.5 9.7 
Statin 50.7 54.0 60.2 61.1 
SSRI 55.5 62.0 51.0 53.1 
ACE inhibitor or ARB 53.7 57.6 48.8 51.6 
Select Comorbidities,† %     
Diabetes 41.0 41.3 41.8 41.9 
Heart failure 49.0 45.0 50.3 45.7 
Hypertension 84.2 85.5 87.4 88.1 
Coronary artery disease 31.2 30.8 30.0 28.5 
Anemia 32.4 32.5 33.9 32.5 




Stroke 24.2 26.8 15.7 16.7 
CHA2DS2-Vasc Risk Score, %     
2-3 11.2 12.6 12.7 13.9 
4 22.6 19.5 23.8 24.8 
5 27.3 27.0 30.2 29.9 
6 21.7 22.4 20.9 19.7 
7+ 17.3 18.6 12.4 12.5 









Intermediate (4)  4.6 5.4 6.3 6.6 
High (5-10)  34.8 32.0 39.6 35.8 
Cognitive skills, %     
Mildly impaired  26.0 28.3 25.9 27.1 




ADL score (0-16), ‡ median (Q1, 
Q3) 
9 (6, 11) 9 (6, 11) 
9 (7, 11) 9 (7, 11) 
*Any Part D claim during the 12-month period 
†Resident characteristics exclude residents with missing values for fall history, heart failure, 
hypertension, diabetes, and stroke (n<10 for all characteristics with missing values in 2011 and 2016). 
‡Higher scores indicate greater limitation in ADLs 
Abbreviations: activities of daily living (ADLs), non-steroidal anti-inflammatory drugs (NSAID), 
selective serotonin reuptake inhibitor (SSRI), angiotensin converting enzyme (ACE), angiotensin 






























N, total 17,895 33,959 33,493 33,956 35,709 37,118 36,183 36,379 36,807 37,644 37,474 37,787 
Treated, * % 42.4 42.3 43.1 42.8 42.7 42.8 43.7 44.3 44.8 45.5 47.0 47.8 
Warf., % 40.5 39.4 39.4 38.4 37.0 35.2 33.6 31.8 30.6 29.0 27.3 24.7 
DOAC, % 1.9 2.9 3.7 4.3 5.6 7.7 10.2 12.5 14.2 16.5 19.7 23.1 
Dab.,† 1.9 2.9 3.3 3.1 2.7 2.6 2.7 2.6 Sup. Sup. Sup. 2.2 
Riv., 0.0 0.0 0.4 1.2 2.9 4.6 6.2 7.1 7.1 7.3 7.8 8.3 
Apix., 0.0 0.0 0.0 0.0 0.1 0.5 1.3 2.8 4.7 7.0 9.8 12.6 
Edox.,† 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 Sup. Sup. Sup. 0.1 
*Treated percentage may not equal the sum of warfarin and DOAC percentages due to rounding 
†Cell values suppressed to prevent any individual cell size from being <11 





Table 2.5 Percentage of Nursing Home Residents with Atrial Fibrillation Treated 
with Oral Anticoagulants by Cognitive Status and Functioning in ADLs 

















n 20,338 13,621 24,660 13,127 
Treated, (%) 46.4 36.1 51.7 40.4 
ADL Score 0 to 
4,* n 
4,275 772 4,076 677 
Treated, % 46.9 33.0 51.7 40.9 
ADL Score 5 to 
8,* n 
6,401 2,470 7,714 2,349 
Treated, % 45.5 35.7 51.5 43.1 
ADL Score 9 to 
12,* n 
8,195 5,953 11,501 6,850 
Treated, % 47.1 37.0 52.3 40.3 
ADL Score 13 to 
16,* n 
1,467 4,426 1,369 3,251 
Treated, % 45.5 35.7 48.1 38.7 
*|Higher scores indicate greater limitation in ADLs 









Table 2.6 Anticoagulant Use by Renal Function among Nursing Home Residents 
with Atrial Fibrillation 











December 31, 2016     
n 18,606 10,956 7,014 1,211 
Treated, (%) 47.8 48.5 47.1 44.2 
Warfarin, (%) 24.0 24.2 25.8 33.1 
Low dose 
DOAC, (%) 
10.5 12.9 12.8 7.7 
Standard dose 
DOAC, (%) 
13.4 11.4 8.4 3.4 
December 31, 2011     
n 19,319 9,116 4,713 811 
Treated, (%) 43.1 42.8 38.5 39.7 
Warfarin, (%) 40.0 39.8 36.1 39.7 
Low dose 
DOAC, (%) 
0.8 1.4 1.3 0.0 
Standard dose 
DOAC, (%) 
2.2 1.6 1.1 0.0 
*Identified from inpatient diagnoses. Corresponds to an estimated glomerular 
filtration rate <60 ml/min. Residents with evidence of more severe disease (end stage 
renal disease or on dialysis) were assigned to the more severe category. 
†Identified from the most recent MDS 3.0 assessment (item I1500: end stage renal 
disease). Residents with evidence of more severe disease (on dialysis) were assigned 
to the more severe category. 
‡Identified from the most recent MDS 3.0 assessment (item O0100J2) which indicates 
whether the resident has received dialysis within the last 14 days while a resident of 
the nursing facility. 






Table 2.7 Percentage of Residents Treated with Oral Anticoagulants by 
Race/Ethnicity 




First half 2011       
n 17,895 15,404 1,421 688 257 125 
Treated, % 42.4 42.6 41.5 42.4 32.7 43.5 
Second half 
2011 
      
n 33,959 29,268 2,623 1,316 530 222 
Treated, % 42.3 42.8 40.3 39.7 31.7 39.9 
First half 2012       
n 33,493 28,766 2,690 1,297 507 233 
Treated, % 43.1 43.4 43.1 40.2 35.7 44.6 
Second half 
2012 
      
n 33,956 29,062 2,724 1,357 554 269 
Treated, % 42.8 43.2 42.0 39.9 32.9 37.8 
First half 
2013*  
      
n 35,709 30,532 2,836 1,371 571 283 
Treated, % 42.7 43.2 40.6 40.8 31.4 40.7 
Second half 
2013* 
      
n 37,118 31,524 2,926 1,454 590 300 
Treated, % 42.8 43.5 40.9 39.1 29.3 39.0 
First half 2014       
n 36,183 30,808 3,041 1,425 587 322 
Treated, % 43.7 44.4 42.3 39.4 30.7 41.3 
Second half 
2014 
      
n 36,379 31,013 3,035 1,407 585 339 
Treated, % 44.3 44.8 43.0 40.9 32.3 41.3 
First half 2015       
n 36,807 31,490 3,071 1,354 560 332 
Treated, % 44.8 45.3 43.8 42.5 31.6 43.7 
Second half 
2015 
      
n 37,644 32,222 3,068 1,410 595 349 
Treated, % 45.5 46.0 43.8 43.0 33.8 43.8 
First half 2016       





Treated, % 47.0 47.4 47.7 42.9 37.6 43.7 
Second half 
2016 
      
n 37,787 31,985 3,255 1,578 608 361 
Treated, % 47.8 48.3 46.5 42.3 36.7 54.3 
*Race/ethnicity missing for 116 residents in the first half of 2013 and 324 residents in 
the second half of 2013 




GEOGRAPHIC VARIATION IN ANTICOAUGLANT USE AND RESIDENT, 
FACILITY, AND COUNTY CHARACTERISTICS ASSOCIATED WITH 









Anticoagulation decisions for older adults with atrial fibrillation residing in nursing 
homes are complicated by the presence of both vascular and bleeding risk factors. Our 
objective was to quantify geographic variation in anticoagulant use and explore what 
resident, facility, and county characteristics were associated with anticoagulant use in a 
clinically complex population. 
Methods 
Long-stay nursing home residents (>65 years) with a diagnosis of atrial fibrillation and 
>6 months of Medicare fee-for-service enrollment preceding the point prevalence date 
were eligible. Medicare Parts A and D were linked to the Minimum Data Set 3.0, facility 
level files, and the Area Health Resources File. The point prevalence of oral 
anticoagulant use was estimated on December 31st 2014, 2015, and 2016 using a repeated 
cross-sectional design with a 12-month lookback period. Multilevel logistic models 
evaluated the extent to which variation in anticoagulant use between counties could be 
explained by resident, facility, and county characteristics, and state of residence. 
Proportional changes in cluster variation (PCV), intraclass correlation coefficients (ICC), 
and adjusted odds ratios (aOR) were calculated. 
Results 
Among 89,176 eligible nursing home residents from 12,159 facilities and 1,722 counties, 
70.6% was ≥ 80 years, 50% had renal impairment, 63% had cognitive impairment, and 





anticoagulants 20% higher in 2016 than 2014 (aOR: 1.21; 95% confidence interval: 1.17 
– 1.25). Most states were composed of counties in the highest (48% to 58%) and lowest 
(31% to 41%) quintiles of anticoagulant use. Compared with the null model, adjustment 
for resident characteristics increased variation between counties (PCV: -24.4%). The full 
model explained 38.4% of the between-county variation. Within county correlation was a 
small proportion (ICC<2.3%) of total variation in all models.  
Conclusion 
Adjustment for resident characteristics, including clinical risk factors that typically drive 
treatment decisions, did not explain and instead increased the variation in anticoagulant 
use between counties. Comparative evidence and refinement of predictive algorithms 
specific to the nursing home setting may be warranted to guide residents, family, and 







 Anticoagulation is highly effective for ischemic stroke prevention for individuals 
with atrial fibrillation,25 yet fewer than one in three nursing home residents with atrial 
fibrillation were treated with oral anticoagulants (i.e., warfarin) during the early 
2000s.49,51 The use of oral anticoagulants among nursing home residents with atrial 
fibrillation has since increased substantially, with nearly one-half of residents receiving 
treatment as of the end of 2016.99 Circumstances likely contributing to this increase 
during the intervening period included broad-based quality improvement efforts in the 
United States healthcare system100 (and targeting nursing homes specifically99), the 
release of trial results specific to an older adult population which convincingly 
demonstrated real-world safety and effectiveness of anticoagulation with warfarin,59 and 
the availability of four direct acting oral anticoagulants (DOACs) which have expanded 
therapeutic options for patients and providers. 
Despite a nearly 20% increase in anticoagulant use,99 the fraction of nursing home 
residents with atrial fibrillation receiving anticoagulants remains lower than in 
community dwelling Medicare population.44 This difference may be appropriate in light 
of limited life expectancy75 and other factors that may alter patient and clinician 
judgements of the net benefit of treatment. Anticoagulation decisions for older adults 
with atrial fibrillation, particularly those residing in nursing homes, are complicated by 
the presence of both vascular and bleeding risk factors.100 Shared-decision making, as is 
recommended by current practice guidelines,24 is challenging for this population with a 





the absolute risk of ischemic stroke and bleeding (and the consequences of each outcome) 
under alternative treatment scenarios. 
Recognizing the limited availability of evidence to guide anticoagulation 
decisions for older nursing home residents with atrial fibrillation, our objective was to 
explore what resident, facility, and county characteristics were associated with 
anticoagulant use for this clinically complex and vulnerable population. Fundamental to 
this objective is the goal of identifying sociodemographic, clinical, and health system 
factors that may be amenable to clinical and health policy interventions. Considering that 
absolute differences on clinical risk scores81-83 predicting ischemic stroke and bleeding 
risk are small between treated and untreated residents,99 we hypothesized that in addition 
to risk factors included in summary scores, multiple other sociodemographic (e.g., age, 
Medicaid enrollment), clinical (e.g., medication use), and functional characteristics of 
residents would be associated with anticoagulant use. Furthermore, because of the large 
role for patient preference and clinician judgement in current clinical practice for this 
population, we expected to observe concordance in treatment patterns within local areas 
(i.e., counties) with shared personal values and healthcare providers.  
Data 
Medicare beneficiary enrollment and vital status (Master Beneficiary Summary 
File), hospital and skilled nursing facility utilization (Medicare Part A), medication 
dispensing records (Medicare Part D), and nursing home assessments (Minimum Data Set 
(MDS) 3.0) were accessed through a data use agreement with the Centers for Medicare 





intervals in Medicare/Medicaid certified nursing homes and the data collected using the 
MDS 3.0 has been previously validated.67 Facility characteristics were obtained from the 
Nursing Home Compare and the Certification and Survey Provider Enhanced Reporting 
(CASPER) files. Sociodemographic and health resources at the county level were linked 
from the Area Health Resources File. The University of Massachusetts Medical School 
Institutional Review Board approved this study (H00015376). 
Study Design 
The point prevalence of oral anticoagulant use was estimated on December 31st 
2014, 2015, and 2016 using a repeated cross-sectional design with a 12-month lookback 
period. 
Study Population 
Long-stay nursing home residents (>65 years of age) with a diagnosis of atrial 
fibrillation and at least 6 months of Medicare fee-for-service enrollment preceding the 
point prevalence date were eligible. At least one diagnosis of atrial fibrillation102 on a 
Medicare Part A claim and one diagnosis of atrial fibrillation, atrial flutter, or 
dysrhythmia on an MDS 3.0 assessment were required. For residents eligible at multiple 
point prevalence dates, a single cross-section was selected at random. Residents in a 
coma and those without a Part D claim in the 12-month lookback period were excluded. 
Residents on hospice, in a hospital, or in a skilled nursing facility on the point prevalence 
date were excluded because medications are not reimbursed by Medicare Part D in these 
settings. Counties with fewer than 11 residents (1,499 of 3,221 counties) were excluded, 






Current use of an oral anticoagulant (apixaban, dabigatran, edoxaban, 
rivaroxaban, warfarin) was measured on the point prevalence date as the number of 
residents with medication on hand divided by the number of residents in the eligible 
population. Using dispensing dates and number of days supply, exposure status was 
recorded for each day of the cross-section while accounting for early medication fills, 
hospitalizations, and skilled nursing facility stays.  
Resident Characteristics 
Characteristics of the resident population were summarized from Medicare claims 
from the 12 months preceding the point prevalence date and from information on the 
most recent MDS 3.0 assessment. These included sociodemographic characteristics (age, 
sex, race/ethnicity, marital status, dual Medicare-Medicaid enrollment), number of 
hospital admissions, hospitalizations for certain conditions identified using diagnoses on 
Part A claims (ischemic stroke,79 extracranial bleeding,80 intracranial hemorrhage,80 
myocardial infarction,103 venous thromboembolism,104 or transient ischemic attack), 
CHA2DS2-Vasc ischemic stroke risk score and its components,
81 ATRIA bleeding risk 
score and its components,82 other conditions associated with risk or perceived risk of 
bleeding (fall history,41,51 renal impairment83,84), total unique medications used (a proxy 
for polypharmacy), specific medication classes associated with stroke and/or bleeding 
risk (angiotensin converting enzyme inhibitors/angiotensin receptor blockers,105 non-





inhibitors,85,86 statins108), functional status (activities of daily living score),87 and 
cognitive impairment (the MDS 3.0 Cognitive Function Scale).74  
Facility Characteristics 
Nursing home facility characteristics were conceptually classified as either 
structural, resource, staffing, or quality of care. Structural characteristics included size 
(number of beds) and specialized service availability for on-site residents (specialized 
rehabilitation, pharmacy, laboratory, hospice). Larger facilities and those with 
rehabilitation services were expected to be associated with a larger volume of residents 
with atrial fibrillation, potentially developing internal expertise or attracting external 
expertise into the nursing home, while availability of laboratory services may make it 
easier to monitor therapy. 
Characteristics representing resources available to the facility included 
occupancy, for-profit status, and status as an individual or corporate entity. Not-for-profit 
facilities109 and those with greater resources have traditionally achieved better care 
quality.110 Facilities with greater resources, and those with multisite facilities, may be 
more predisposed to having programs (e.g., quality improvement), infrastructure (e.g., 
clinical decision support) and protocols in place that are associated with guideline 
adherence. Higher staffing has also been found to be positively associated with quality of 
care.111 Staffing was operationalized as quartiles of the minutes per resident-day of care 
from nurses and nursing assistants (i.e., all nursing care), registered nurses (RN), all 
prescribers (medical director, other physicians, physician extenders), medical directors, 





physician extenders was also included to evaluate if prescriber type was associated with 
prescribing decisions. Quality of care in the facility was operationalized using the overall 
5-star nursing home compare rating, which has been found to be associated with 
medication safety.112  
County Characteristics 
Wide regional variation exists within the United States in adherence to guideline 
recommendations for primary and secondary prevention for atherothrombosis.113 To 
understand the contribution of county-level factors to variation in anticoagulant use in the 
nursing home setting, we considered socioeconomic factors, health system supply factors, 
and cerebrovascular risk. Counties were grouped using the 2013 Rural/Urban Continuum 
Codes114 as either metropolitan, urban and metropolitan adjacent, urban and not 
metropolitan adjacent, rural and metropolitan adjacent, and rural not metropolitan 
adjacent. Sociodemographic factors categorized as quartiles included the proportion of 
the older adult (>65 years) population on Medicaid and the proportion of older adults in 
deep poverty, the proportion of the Medicare eligible residents enrolled in Part D, the 
proportion of the overall population that was white, without a high-school education, and 
the proportion of single parents. Other socioeconomic factors included whether the 
county was classified as experiencing population loss and persistent poverty.  
On the health system supply side, quartiles of the ratio of total physicians to the county 
population, the fraction of total physicians in primary care, and the ratio of cardiologists 
and neurologists to the population were considered because provider type has been found 





fibrillation.76,77 Because geriatricians are accustomed to the management of nursing home 
residents, the presence of >1 hospital with a geriatric service was also included as a 
potential predictor (community based supply was not available). The presence of at least 
one hospital with a medical school was included as a potential facilitator of the 
dissemination of best practices and new technologies, while quartiles of the ratio of 
hospitals to land area (square miles) was included as an indicator of access to tertiary 
care. Finally, cerebrovascular risk was operationalized as the number of deaths from 
cerebrovascular disease per resident in the population. 
Geographic Variation 
Variation in prescribing quality for Medicare beneficiaries has been documented 
across healthcare markets and states,115 and variation in prescribing of opioids has been 
observed in the nursing home population.117 To examine within and between state 
variation in prescribing of oral anticoagulants, we grouped residents into counties and 
states. We chose to use counties as the healthcare market to incorporate county-level 
characteristics describing local health system supply factors and sociodemographic 
information. Furthermore, because counties do not cross state lines, differences in state 
policies can be largely excluded as a potential source of variability in prescribing 
observed between counties within states. We also evaluated interstate variation because 







Descriptive statistics first summarized the study population by anticoagulation 
status for resident, facility, and county level characteristics. Medians with first and third 
quartiles were calculated for continuous variables and frequencies with percentages were 
calculated for categorical variables.  
Statistical tests were performed to test whether two level (versus one level) and 
three level (versus two level) variance components models were better fits for the data. 
Then, to evaluate the extent to which variation in anticoagulant use between counties 
could be explained by resident characteristics, facility characteristics, county 
characteristics, and state, we fit five multilevel logistic models: 1) an intercept only 
model with random intercepts of counties (null model), 2) resident characteristics only, 3) 
adding facility characteristics, 4) county characteristics, and 5) adding random intercepts 
for states. Time (year) was included in all models as a fixed effect. To compare county’s 
observed prevalence of anticoagulant use with the prevalence that would be expected 
based the composition of its resident population (i.e., observed versus predited), we also 
fit a single level logistic model with only resident characteristics and time.  
The proportional change in cluster variation (PVC)118 was estimated across 
multilevel models to characterize the between-county variation attributable to the 
explanatory factors included in each model. Intraclass correlation coefficients (ICCs) 
were also calculated to quantify the magnitude of correlation between residents within 
counties (all models) and within states across counties (for the model with random 





and county characteristics, adjusted odds ratios (aOR) and 95% confidence intervals (CI) 
were estimated from the full model with random intercepts for states. 
Results 
During the 2014, 2015, and 2016 cross-sections, 45% of the 89,176 long-stay 
nursing home residents diagnosed with atrial fibrillation were using oral anticoagulants. 
Residents were included from 12,159 facilities located in 1,722 counties (number of 
residents in median county: 27, Q1 17, Q3 50). More than two-thirds (70.6%) of the 
population was older than 80 years, 67.3% were women, and 79.3% were dual Medicare-
Medicaid enrollees. Half of residents had renal impairment, 62.6% had at least mild 
cognitive impairment, and 20.0% had a recent fall. The median facility size was 108 beds 
and the median facility occupancy was 86.7%. Physician extenders contributed 26.1% of 
the prescriber minutes at the median facility (Q1 0.0, Q3 58.8). Most facilities were for-
profit (74.1%) and most were part of a chain (62.0%). Most counties were metropolitan 
(50.9%) or urban (44.8%). The median county had a ratio of 13.2 physicians, 0.2 
cardiologists, and 0.1 neurologists per 10,000 persons. The median county experienced 
52.7 cerebrovascular deaths per 10,000 persons per year.  
 Resident, facility, and county characteristics of treated and untreated residents are 
presented in Table 3.1. Among treated residents, 9.1% had been hospitalized for an 
ischemic stroke and 5.4% for an extracranial bleed in the prior year, compared with 5.9% 
and 8.2% of untreated residents. The proportion of treated and untreated residents with 





scores indicating high bleeding risk were 37.4% and 43.0%, respectively. Cognitive 
impairment was present among 57.2% of treated and 67.0% of untreated residents.  
 The unadjusted estimates of anticoagulant use plotted by county (Figure 3.1.a.) 
convey variation between counties within states, between states, and across regions. 
There was a nearly twofold difference between the county with the lowest proportion of 
residents anticoagulated (McLennan, Texas: 31.6%) and the county with the highest 
proportion treated (Pottawattamie, Iowa: 58.3%). Most states were composed of counties 
in the highest (48.1% to 58.3%) and lowest (31.6% to 42.0%) quintiles of anticoagulant 
use, and it was common to observe adjacent counties in the lowest and highest quintiles. 
Regionally, rural counties with an insufficient number of residents for inclusion were 
concentrated in the mountain west and south. In Figure 3.1.b., predicted values for the 
proportion of treated residents in each county based on resident characteristics (without 
county intercepts) were plotted. When compared with values in Figure 3.1.a., these 
population average estimates suggest that clusters of counties in certain regions (e.g., the 
Northeast) appear to have higher treated fractions than would be expected based solely on 
the characteristics of their residents, while for other regions the inverse may apply (e.g., 
the Pacific Northwest).  
 The adjusted odds ratios for several resident characteristics underscore the relative 
importance of clinical factors for prescribing decisions relative to facility and county 
contextual effects (Table 3.2). Compared with residents younger than 80 years, those >90 
had 40% lower odds of receiving anticoagulation. Recent hospitalization for intracranial 





0.58-0.66), severe cognitive impairment (aOR: 0.45; 95% CI : 0.42-0.48), and antiplatelet 
use (aOR: 0.32; 95% CI: 0.30-0.33) each exhibited large negative associations with 
treatment. The associations of facility and county characteristics were modest with aORs 
in the range of 0.92 to 1.17. Non-profit facilities, rural counties, and the highest quartile 
of Medicare Part D plan participation were each associated with increased odds of 
anticoagulant use of 12% to 17%. The odds of using oral anticoagulants was 20% higher 
in 2016 compared with 2014. 
 Compared with the null model with only random intercepts for counties, resident 
characteristics (PCV: -24.4%) and resident plus facility characteristics (PCV: -12.4%) 
increased the variation between counties (Table 3.3). The model with resident, facility, 
and county characteristics explained 13.2% of the between-county variation (versus the 
null model) and the model with resident characteristics, facility characteristics, county 
characteristics and random state intercepts explained 38.4% of the between-county 
variation. Within county correlation was weak in each of the models with only county 
random intercepts (ICCcounty: 0.016 to 0.023). In the fully adjusted model with random 
county and state intercepts the probability of prevalent oral anticoagulant use was more 
closely correlated for two residents in the same county (ICCcounty: 0.011) than for two 
residents in different counties within the same state (ICCstate: 0.006).  
Discussion 
 In this large national study of United States nursing home residents with atrial 
fibrillation, we found that much of the variation in prevalent oral anticoagulant use 





factors for ischemic stroke and bleeding outcomes were strongly associated with 
treatment. As hypothesized, we observed correlation within counties. The proportion of 
residents using oral anticoagulants was 48-58% in the top quintile of counties and 32-
42% in the bottom quintile of counties. Providers in different areas were less similar in 
their prescribing practices after accounting for individual residents’ factors. When facility 
and county characteristics were introduced into the model, the increase in between-
county variation from the addition of resident characteristics was fully offset. In the 
context of clinically significant variation of 24% between the highest and lowest 
counties, the magnitude of variation between individuals was sufficiently large for this 
seemingly large county level variation to represent less than two percent of the total. We 
postulate that this highly individualized treatment paradigm is both a manifestation of 
provider uncertainty stemming from inadequate evidence to standardize clinical practice 
and, perhaps to a lesser extent, an encouraging signal of a resident-centered process of 
shared decision-making. 
The clinical guideline from the American Heart Association, the Heart Rhythm 
Society, and the American College of Cardiology recommends anticoagulation for 
patients with atrial fibrillation and a CHA2DS2-Vasc risk score of at least two on the basis 
of Level A evidence.24 Despite a clear recommendation for the use of anticoagulants, 
many individuals do not receive treatment, even among less medically complex 
community dwelling populations.40,44 The prevalence of anticoagulant use has been 
estimated to be 70% among older adults enrolled in Medicare Supplemental coverage,44 





prevalence of anticoagulant use in nursing homes should be lower than in the community 
because of differences between these populations. However, resident, family, and 
provider perceptions of the role for resident factors such as advanced age and cognitive 
impairment, which we found to be strongly associated with anticoagulant use, has not 
been well established.  
More than 60% of the nursing home population with atrial fibrillation had 
cognitive impairment, and only two percent were fully independent in performance of 
activities of daily living. Residents with cognitive impairment were substantially less 
likely to receive anticoagulants, consistent with prior nursing home literature.52,90 
Intuitively, the benefit of stroke prevention diminishes with declining function because of 
floor effects with a lower baseline, limiting the potential for further loss of function in the 
event of a stroke. Yet the large variability in prevalent use of anticoagulants for 
individuals and geographically suggests that the wealth of information on clinical 
conditions, medications used, cognitive impairment, and physical functioning available to 
providers in the nursing home setting may not be used in a systematic manner. While 
variation introduced through a resident-centered shared decision-making process is 
appropriate,24 predictive information on the absolute probability and functional 
consequences of ischemic stroke and major bleeding events under alternative treatment 
scenarios is necessary, and presently unavailable, to inform such a process.  
Facility characteristics explained approximately one-tenth of the variation in 
anticoagulant use between counties, after accounting for resident characteristics. The 





profit owned facilities, regardless of whether the non-profit was a chain. During our study 
period, two-thirds of Medicare eligible Veterans Affairs beneficiaries with atrial 
fibrillation were receiving anticoagulation,120 which suggests substantially lower 
anticoagulant use in Veterans Affairs nursing facilities compared with the general 
Veterans Affairs population and may also reflect incomplete capture of anticoagulant use 
in Veterans Affairs nursing homes by Medicare Part D claims. Overall nursing home 
quality was modestly associated with a higher prevalence of anticoagulant use. 
Prescribing quality, as measured by rates of medication errors and serious medication 
errors, has been found to be correlated with the overall nursing home quality ratings.112 
Nursing home staffing was not associated anticoagulant prescribing, although detailed 
information on the frequency and type of provider-patient interactions is not available in 
the CASPER and Nursing Home Compare files. Contextual variables describing the 
supply of cardiology, neurology, and geriatrics at the county level were evaluated 
because of earlier findings of variability in prescribing patterns by provider type.76,77 
Although no strong associations were found, further investigation is needed to understand 
resident access to specialist providers in the nursing home setting.  
Several sociodemographic factors were associated with anticoagulant use. 
Residents who were currently married, a form of social support and connectivity 
associated with more aggressive care at the end of life,121 had slightly higher odds of 
anticoagulant use. The positive association of county level Medicare Part D participation 
with anticoagulant use may also be a product of better social support structures and health 





program has been cited as a potential contributor to lower enrollment among several 
subgroups including those with low income, low educational attainment, and those of 
Hispanic ethnicity.122,123 Variation in anticoagulant use was observed between individuals 
of different races/ethnicities and between counties with varying racial/ethnic 
composition. Compared with black/African American residents (among whom 
anticoagulant use was highest), Hispanic residents and Asian/Pacific Islanders were less 
likely to use anticoagulants. Counties with the highest proportion of white residents had 
18% higher odds of anticoagulant use, consistent with earlier findings of better processes 
and outcomes in nursing homes with higher proportions of white residents119 and better 
quality of care in nursing homes located in neighborhoods with fewer minority 
residents.32 
This study used a repeated cross-sectional design and applied multilevel modeling 
to explore geographic variation in anticoagulant use and variation associated with 
specific factors. This study builds on earlier work demonstrating an increase in 
anticoagulant use during 2014-2016,99 and confirms that this increase cannot be 
explained by changes in observed resident characteristics. The present study has 
limitations. Medication use was operationalized using information from Medicare Part D 
claims, which may not represent actual medication use. However, in the nursing home 
setting, adherence is typically not of concern as administration of medications are 
overseen by medical personnel. Over the counter medications including aspirin are 
typically not recorded in Part D. The results should not be generalized to sparsely 





11 eligible residents during 2014-2016 were excluded. Finally, although we studied a 
large set of important resident, facility, and county factors, it is likely that other 
individual (e.g., number and proximity of children) and provider/facility (e.g., availability 
of specialist providers, targeted clinical programs and protocols) factors influence 
medication use. 
Conclusion 
Variation in anticoagulant use between counties among nursing home residents 
with atrial fibrillation ranged from a minimum of 32% to a maximum of 58%. 
Adjustment for resident characteristics, including clinical risk factors for ischemic stroke 
and major bleeding that typically drive treatment decisions, did not explain and instead 
increased the variation in prescribing between counties. Correlation in anticoagulant use 
within counties and states was small as a proportion of total variation. Comparative 
evidence and refinement of predictive algorithms specific to the nursing home setting 
may be warranted to inform residents, family, and providers making difficult decisions 






Table 3.1. Characteristics of Residents Treated or Not Treated with an 





Demographics   
Age in years, median (Q1, Q3) 84 (77, 89) 86 (79, 91) 
Women, % 67.2 67.4 
Married, % 21.6 19.9 
Medicaid eligible, % 79.0 78.7 
Race/ethnicity, %   
White 88.0 86.4 
Black 8.4 8.8 
Hispanic 1.3 1.7 
Asian/Pacific Islander 1.1 1.8 
Other/Unknown 1.2 1.3 
Time since first observed nursing home 
admission, median (Q1, Q3) 
821 (330, 1471) 822 (330, 1463) 
Hospital admissions in prior year, %   
1 46.7 48.9 
2-3 37.2 36.0 
4+ 13.1 12.1 
Ischemic stroke 9.1 5.9 
Transient ischemic attack 1.7 1.2 
Extracranial bleed 5.5 8.3 
Intracranial hemorrhage 0.6 1.6 
Venous thromboembolism 4.0 1.6 
Acute myocardial infarction 3.6 4.6 
Unique medications, median (Q1, Q3) 19 (14, 24) 16 (12, 22) 
Select prescription medications,* %   
Nonsteroidal anti-inflammatory drug 16.1 17.5 
Antiplatelet 8.5 19.1 
Statin 59.7 50.0 
Selective serotonin reuptake inhinitor 52.4 49.8 
Angiotensin converting enzyme inhibitor or 
Angiotensin II receptor blocker 
51.4 46.9 
Select comorbidities, %   
Diabetes mellitus  35.2 
Heart failure 48.1 41.4 
Hypertension 87.6 85.7 
Coronary artery disease 30.9 32.5 
Peripheral vascular disease 15.4 13.4 





Fall history   
Fall with fracture in six months before last 
admission 
1.1 1.1 
Fall since admission 18.2 21.5 
Hip fracture 2.5 2.9 
Stroke 18.4 14.7 
Aphasia 4.9 3.9 
Hemiplegia 12.5 7.9 
Renal impairment   
Chronic renal insufficiency 31.0 30.2 
End-stage renal disease 16.1 16.7 
Dialysis 3.0 3.3 
CHA2DS2-Vasc Risk Score, %   
2-3 11.8 14.7 
4 22.4 25.6 
5 28.2 27.5 
6+ 37.6 32.2 
ATRIA Bleeding Risk Score, %   
Low (0-3) 55.4 50.0 
Intermediate (4) 7.0 6.8 
High (5-10) 37.6 43.2 
Level of cognitive impairment, %   
Mildly impaired 26.8 26.1 
Moderately to severely impaired 30.4 41.0 
Activities of daily living score (0-16), 





Facility characteristics   
Number of beds, median (Q1, Q3) 120 (95, 161) 120 (97, 161) 
Occupancy (percentage of beds), median 
(Q1, Q3) 
88.4 (79.9, 94.0) 88.6 (80.0, 94.0) 
Non government chain, % 76.4 76.4 
For profit ownership, % 70.2 71.6 
Nursing home compare overall rating, %   
1-2 33.6 34.4 
3 19.7 19.5 
4-5 46.7 46.1 
Clinical lab available, % 81.2 81.3 
Medical director, % 89.7 90.2 
Physician and extender minutes/resident/day, 
median (Q1, Q3) 
2.4 (0.9, 4.7) 2.5 (0.94, 4.8) 
Percentage of minutes from physician 
extenders, median (Q1, Q3) 





Nursing minutes per resident per day, 





Percentage of minutes from registered 
nurses, median (Q1, Q3) 
11.6 (7.7, 16.4) 11.3 (1.3, 16.0) 
Pharmacist minutes per resident per day, 
median (Q1, Q3) 
0.9 (0.0, 1.6) 0.9 (0.0, 1.6) 
Hospice beds, % 1.0 1.1 
Special rehabilitation services, % 3.0 3.0 
County characteristics    
Area sociodemographics   
Proportion of adults >65 eligible for 
Medicaid, median (Q1, Q3) 
12.0 (8.8, 16.6) 12.1 (8.8, 16.7) 
Proportion of adults >25 years of age 
without high school diploma, median (Q1, 
Q3) 
7.8 (6.2, 10.1 7.9 (6.2, 10.2) 
Proportion white race/ethnicity, median 
(Q1, Q3) 
81.2 (68.3, 90.8) 80.0 (66.3, 90.1) 
Proportion >65 years in deep poverty, 
median (Q1, Q3) 
2.5 (2.1, 3.1) 2.5 (2.1, 3.2) 
Single parent households per 10,000 





Population density (persons per square 





Urban-rural continuum, %   
Metro area 76.5 77.9 
Urban area metro adjacent  15.1 14.3 
Urban not adjacent to metro 7.1 6.7 
Rural 1.3 1.0 
County experiencing population loss, % 5.0 5.1 
County experiencing persistent poverty, % 9.3 8.2 
Proportion of eligible enrolled in Medicare 
Part D, median (Q1, Q3) 
49.5 (40.3, 56.9) 48.5 (38.8, 55.9) 
Area healthcare resources   
Facilities   
Hospitals per 100 square miles, median 
(Q1, Q3) 
0.6 (0.2, 1.7) 0.6 (0.2, 1.8) 
At least 1 hospital with geriatric services, 
% 
68.1 69.1 
At least 1 medical school affiliated 
hospital, % 
60.9 62.1 
Providers   
Physicians per 10,000 persons, median 
(Q1, Q3) 





Cardiologists per 10,000 persons, median 
(Q1, Q3) 
0.6 (0.3, 1.0) 0.6 (0.3, 1.0) 
Neurologists per 10,000 persons, median  
(Q1, Q3) 
0.4 (0.2, 0.7) 0.4 (0.2, 0.7) 
Primary care as fraction of all 
physicians, median (Q1, Q3) 
30.1 (23.6, 37.9) 29.6 (23.4, 37.2) 
Pharmacists per 10,000 persons, median 
(Q1, Q3) 
1.4 (0.8, 2.2) 1.4 (0.9, 2.2) 
At least 1 hospice provider, % 83.7 85.1 
Health   
Cerebrovascular deaths per 10,000 
persons, median (Q1, Q3) 
4.4 (3.5, 5.4) 4.4 (3.5, 5.4) 







Table 3.2. Adjusted Odds of Receiving Treatment with an Oral Anticoagulant by 
Resident, Facility, and County Characteristics 




2015 1.05 (1.02-1.09) 
2016 1.21 (1.17-1.25) 
Demographics  
Age in years  
<80 years Reference 
80-84 years 0.98 (0.93-1.02) 
85-89 years 0.88 (0.85-0.92) 
>90 years 0.60 (0.59-0.63) 
Men 0.99 (0.95-1.04) 
Married 1.06 (1.02-1.10) 
Medicaid eligible 0.97 (0.93-0.91) 
Race/ethnicity  
Black/African American Reference 
Non-Hispanic White 0.95 (0.90-1.00) 
Hispanic 0.85 (0.75-0.97) 
Asian/Pacific Islander 0.70 (0.61-0.80) 
Other/Unknown 0.91 (0.79-1.04) 
Time since first observed nursing home admission   
Q1 Reference 
Q2 0.94 (0.90-0.98) 
Q3 0.92 (0.88-0.96) 
Q4 0.92 (0.88-0.96) 
Hospital admissions in prior year  
0 Reference 
1 0.95 (0.87-1.03) 
2 0.90 (0.82-0.98) 
3 0.85 (0.77-0.93) 
4+ 0.78 (0.71-0.85) 
Ischemic stroke 1.54 (1.44-1.64) 
Transient ischemic attack 1.39 (1.23-1.58) 
Extracranial bleed 0.62 (0.58-0.66) 
Intracranial hemorrhage 0.28 (0.24-0.33) 
Venous thromboembolism 2.88 (2.63-3.16) 
Acute myocardial infarction 0.89 (0.82-0.95) 






Q2 1.61 (1.55-1.68) 
Q3 2.02 (1.93-2.11) 
Q4 2.45 (2.33-2.58) 
Select Medications,*  
Nonsteroidal anti-inflammatory drug 0.87 (0.84-0.91) 
Antiplatelet 0.32 (0.30-0.33) 
Statin 1.42 (1.38-1.47)) 
Selective serotonin reuptake inhinitor 1.02 (0.99-1.05) 
Angiotensin converting enzyme inhibitor or Angiotensin II 
receptor blocker 
1.11 (1.08-1.14) 
Select comorbidities,  
Diabetes mellitus 0.97 (0.93-1.02) 
Heart failure 1.21 (1.16-1.26) 
Hypertension 1.02 (0.97-1.08) 
Coronary artery disease 0.88 (0.85-0.92) 
Peripheral vascular disease 1.19 (1.14-1.25) 
Anemia 0.73 (0.69-0.78) 
Fall history  
Fall with fracture in six months before last admission 0.98 (0.85-1.12) 
Fall since admission 0.85 (0.82-0.88) 
Hip fracture 1.03 (0.94-1.13) 
Stroke 1.16 (1.08-1.23) 
Aphasia 1.18 (1.09-1.27) 
Hemiplegia 1.52 (1.44-1.61) 
Renal impairment 0.85 (0.91-0.89) 
No renal impairment Reference 
Chronic renal insufficiency 0.95 (0.91-0.98) 
End-stage renal disease 0.84 (0.79-0.89) 
Dialysis 0.76 (0.69-0.83) 
CHA2DS2-Vasc Risk Score,  † %  
2-3 Reference 
4 1.13 (1.08-1.19) 
5 1.26 (1.20-1.33) 
6 1.36 (1.29-1.44) 
7+ 1.52 (1.43-1.61) 
ATRIA Bleeding Risk Score,  † %  
Low (0-3) Reference 
Intermediate (4) 0.77 (0.72-0.81) 
High (5-10) 0.71 (0.68-0.73) 





No impairment Reference 
Mildly impaired 0.88 (0.85-0.91) 
Moderately impaired 0.71 (0.69-0.74) 
Severely impaired 0.50 (0.47-0.54) 
Activities of daily living score   
0-4 Reference 
5-8 0.99 (0.94-1.04) 
9-12 0.96 (0.91-1.01) 
13-16 0.79 (0.74-0.85) 
Facility Characteristics  
Number of beds  
Quartile 1 Reference 
Quartile 2 0.95 (0.91-0.99) 
Quartile 3 0.96 (0.91-1.00) 
Quartile 4 0.96 (0.91-1.01) 
Occupancy  
Quartile 1 Reference 
Quartile 2 1.00 (0.95-1.04) 
Quartile 3 1.00 (0.96-1.04) 
Quartile 4 1.00 (0.95-1.05) 
Ownership  
Government Reference 
For profit, individual/partner entity 1.05 (0.97-1.13) 
For profit corporation 1.06 (0.99-1.13) 
Non-profit church or other non-corporation 1.12 (1.03-1.22) 
Non-profit corporation 1.15 (1.06-1.23) 
Nursing home compare overall rating  
1 Reference 
2 0.99 (0.94-1.04) 
3 1.03 (0.98-1.08) 
4 1.04 (0.99-1.10) 
5 1.06 (1.01-1.12) 
Clinical lab available 1.02 (0.98-1.06) 
Medical director 1.02 (0.96-1.08) 
Physician and extender minutes/resident/day  
Quartile 1 Reference 
Quartile 2 0.97 (0.93-1.02) 
Quartile 3 1.00 (0.94-1.05) 
Quartile 4 0.96 (0.90-1.01) 
Proportion of minutes from physician extenders   





Quartile 2 0.98 (0.93-1.04) 
Quartile 3 1.01 (0.97-1.06) 
Quartile 4 1.00 (0.95-1.05) 
Nursing minutes per resident per day  
Quartile 1 Reference 
Quartile 2 1.02 (0.98-1.07) 
Quartile 3 0.99 (0.95-1.04) 
Quartile 4 0.98 (0.94-1.03) 
Proportion of minutes from registered nurses  
Quartile 1 Reference 
Quartile 2 0.99 (0.95-1.03) 
Quartile 3 0.98 (0.93-1.02) 
Quartile 4 0.99 (0.95-1.04) 
Pharmacist minutes per resident per day  
Quartile 1 Reference 
Quartile 2 1.02 (0.97-1.06) 
Quartile 3 1.00 (0.96-1.04) 
Quartile 4 0.99 (0.95-1.04) 
Hospice beds 0.94 (0.81-1.09) 
Special rehabilitation services  0.94 (0.86-1.03) 
County characteristics   
Area sociodemographics  
Proportion of adults >65 eligible for Medicaid  
Quartile 1 Reference 
Quartile 2 1.02 (0.96-1.08) 
Quartile 3 1.02 (0.95-1.10) 
Quartile 4 1.05 (0.96-1.15) 
Proportion of adults >25 years of age without high 
school diploma 
 
Quartile 1 Reference 
Quartile 2 1.04 (0.98-1.11) 
Quartile 3 1.04 (0.97-1.10) 
Quartile 4 1.06 (0.97-1.16) 
White race/ethnicity  
Quartile 1 Reference 
Quartile 2 1.04 (0.97-1.12) 
Quartile 3 1.14 (1.05-1.24) 
Quartile 4 1.18 (1.07-1.30) 
Proportion of adults >65 years of age in deep 
poverty 
 





Quartile 2 0.97 (0.92-1.03) 
Quartile 3 1.00 (0.94-1.06) 
Quartile 4 0.96 (0.89-1.02) 
Single parent households per 10,000 persons   
Quartile 1 Reference 
Quartile 2 1.04 (0.96-1.12) 
Quartile 3 1.01 (0.90-1.13) 
Quartile 4 1.08 (0.93-1.25) 
Population density (persons per square mile)   
Quartile 1 Reference 
Quartile 2 0.92 (0.85-0.99) 
Quartile 3 0.93 (0.84-1.05) 
Quartile 4 0.96 (0.83-1.12) 
Urban-rural continuum  
Metro area Reference 
Urban area metro adjacent  1.00 (0.93-1.07) 
Urban not adjacent to metro 1.00 (0.92-1.09) 
Rural 1.18 (1.00-1.38) 
County experiencing population loss  1.10 (1.02-1.19) 
County experiencing persistent poverty 0.96 (0.96-1.06) 
Proportion of eligible enrolled in Medicare Part D, 
median 
 
Quartile 1 Reference 
Quartile 2 1.05 (0.99-1.12) 
Quartile 3 1.10 (1.03-1.18) 
Quartile 4 1.12 (1.04-1.20) 
Area healthcare resources  
Facilities  
Hospitals per 100 square miles   
Quartile 1 Reference 
Quartile 2 1.07 (1.01-1.13) 
Quartile 3 1.13 (1.03-1.23) 
Quartile 4 1.10 (0.96-1.25) 
At least 1 hospital with geriatric services 0.99 (0.94-1.03) 
Hospitals affiliated with a medical school   
One medical school affiliated hospital in the 
county 
0.98 (0.92-1.03) 
Two or more medical school affiliated hospitals 
in the county 
1.00 (0.92-1.09) 
Providers  





Quartile 1 Reference 
Quartile 2 0.99 (0.92-1.07)) 
Quartile 3 1.00 (0.90-1.12) 
Quartile 4 1.04 (0.90-1.19) 
Primary care as fraction of all physicians   
Quartile 1 Reference 
Quartile 2 1.06 (0.97-1.16) 
Quartile 3 1.09 (0.97-1.16) 
Quartile 4 1.07 (0.95-1.20) 
Cardiologists per 10,000 persons   
Quartile 1 Reference 
Quartile 2 1.02 (0.95-1.09) 
Quartile 3 1.01 (0.93-1.11) 
Quartile 4 1.00 (0.90-1.11) 
Neurologists per 10,000 persons   
Quartile 1 Reference 
Quartile 2 1.01 (0.95-1.07) 
Quartile 3 1.00 (0.92-1.08) 
Quartile 4 0.95 (0.85-1.07) 
Pharmacists per 10,000 persons   
Quartile 1 Reference 
Quartile 2 1.02 (0.97-1.08) 
Quartile 3 1.02 (0.95-1.09) 
Quartile 4 1.03 (0.95-1.12) 
At least 1 hospice provider 0.94 (0.88-0.99) 
Health  
Cerebrovascular deaths per 10,000 persons  
Quartile 1 Reference 
Quartile 2 0.93 (0.87-0.99) 
Quartile 3 0.93 (0.87-1.00) 
Quartile 4 0.92 (0.85-0.99) 
*Individual medication estimates derived from models omitting the number of unique 
medications. 
†CHA2DS2-Vasc Risk Score and ATRIA Bleeding Risk Score estimates derived 






Table 3.3. The Proportional Change in Between-County Variation in Oral 
Anticoagulant Use Explained by Resident Characteristics, Facility 
Characteristics, County Characteristics, and State 












PCV (%) Reference -24.4 -11.8 13.2 38.4 
ICCCounty 0.019 0.023 0.021 0.016 0.011 















Figure 3.1a. Unadjusted Proportion* Receiving Treatment with Oral 
Anticoagulants Among Nursing Homes Residents with Atrial Fibrillation in the 
United States, by County (n=89,176 residents within 12,159 facilities within 1,722 
counties in 2014-2016) 
Figure 3.1.b. Adjusted Proportion† Receiving Treatment with Oral Anticoagulants 
Among Nursing Homes Residents with Atrial Fibrillation in the United States, by 
County (n=89,176 residents within 12,159 facilities within 1,722 counties in 2014-
2016) 
*Estimated from a null two-level logistic model including a random intercept term for 
county level variation. Counties with missing values were those with less than 11 
residents. 
†Estimated from a single-level logistic model adjusted for resident characteristics and 







DIRECT-ACTING ORAL ANTICOAGULANTS VERSUS WARFARIN FOR 
NONVALVULAR ATRIAL FIBRILLATION AMONG UNITED STATSE 








Research comparing direct-acting oral anticoagulants (DOACs) to warfarin has excluded 
nursing home residents, a vulnerable population at high risk for vascular and bleeding 
events.  
Objectives 
To compare the safety and effectiveness of individual DOACS (rivaroxaban, apixaban, 
and dabigatran) versus warfarin among US nursing home residents. 
Methods 
Residents aged >65 years with non-valvular atrial fibrillation newly initiating oral 
anticoagulation and enrolled in fee-for-service Medicare for >6 months were studied. 
Nursing home residence was determined using Minimum Data Set 3.0 assessments. 
Outcomes included 1) ischemic stroke or transient ischemic attack (TIA); 2) bleeding 
(extracranial or intracranial); 3) other vascular events (myocardial infarction, venous 
thromboembolism, systemic embolism) 4) death; and 5) a composite of all outcomes. 
Follow-up continued until an outcome or 14-day treatment gap. DOAC initiators (2,881 
apixaban, 1,289 dabigatran. 3,735 rivaroxaban) were 1:1 propensity matched to residents 
initiating warfarin in the same year. Cox proportional hazards models estimated cause-
specific hazard ratios (HR).  
Results 
Median age (84 years), CHA2DS2-Vasc (5; Q1: 4, Q3: 6) and ATRIA risk scores (3; Q1: 





The incidence of ischemic stroke/TIA ranged from 0.94 to 1.84/100 person-years (PYs) 
and bleeding incidence ranged from 4.35 to 6.74/100 PYs across anticoagulants and 
cohorts. Outcomes differed by anticoagulant, with apixaban having lower bleeding rates 
(HR: 0.66; 95% Confidence Interval (CI): 0.49-0.88)) and higher ischemic stroke/TIA 
rates compared with warfarin (HR: 1.86; 95% CI: 1.00-3.45)). Dabigatran and 
rivaroxaban were comparable to warfarin for ischemic stroke/TIA and bleeding rates. 
Across all anticoagulants mortality rates ranged from 24-40 events/100 PYs. Mortality 
and composite rates were 14-32% lower for each DOAC versus warfarin.  
Conclusions 
In this national study of US nursing home residents, apixaban, rivaroxaban, and 
dabigatran were each associated with lower mortality and composite outcome rates 
compared with warfarin. Although specific DOACs had mixed results for safety and 
effectiveness endpoints, in aggregate, DOACs were being used with equal or greater 






The RE-LY,28 ROCKET-AF,31 and ARISTOTLE29 trials demonstrated superiority 
or non-inferiority in safety and effectiveness for each of the DOACs versus warfarin, but 
excluded nursing home residents. Observational evidence comparing the safety and 
effectiveness of warfarin and the DOACs for older adults has also been limited to 
community dwelling patients.96-98 The generalizability of findings from community 
populations to the nursing home setting is complicated because residents have greater 
functional limitations, cognitive impairment, diminished life expectancy, polypharmacy, 
and the high burden of vascular and bleeding risk factors.99  
Nursing homes are an important health care setting. If the fraction of older adults 
residing in nursing home remains at 2010 levels, the size of the nursing home population 
will increase 77% over the period 2016 to 2050, compared with a 20% increase in the 
size of the American population.71,125 One in six US nursing home residents was 
diagnosed with atrial fibrillation and less than one-third of those with atrial fibrillation 
were treated with warfarin, although these estimates are dated (2004).49 Among those 
treated, approximately half of the time on warfarin was estimated to be outside of the 
therapeutic range.27,51 The prevalence of anticoagulant use has since increased to 48% 
and the mix of anticoagulants used has shifted considerably.99 By 2016 nearly half of 
residents with atrial fibrillation receiving treatment were using direct-acting oral 
anticoagulants (DOACs),99 despite limited evidence to inform anticoagulant and dosage 





The choice of DOAC vs warfarin in the nursing home setting is unclear because 
the balance of risks and benefits is understudied. Clinician concerns regarding increased 
risk of adverse events41,50 influence treatment patterns in nursing homes. However, 
resource inequity and other institutional characteristics introduce variability in treatment 
outcomes due to varied care quality delivered across facilities.126,127 Further, recent 
efforts centered on improving quality of care in nursing homes,101 may have contributed 
to changes in prescribing practices, the quality of warfarin therapy, and outcomes since 
earlier studies of warfarin were conducted.27,48-51 
To address uncertainty regarding the relative safety and effectiveness of the 
DOACs and warfarin in the contemporary nursing home setting, we separately compared 
new-users of apixaban, rivaroxaban, and dabigatran to new-users of warfarin in a national 
cohort of nursing home residents with atrial fibrillation during 2011-2016. Motivated by 
earlier reports describing deviation from labeled dosing recommendations for the 
DOACs,92,99 we also examined heterogeneity in comparative safety and effectiveness 
estimates by dosing alignment. 
Methods 
Data Sources 
Data were obtained and linked through a data use agreement with the Centers for 
Medicare and Medicaid Services. The Master Beneficiary Summary File provided 
information on vital status and enrollment in Medicare and Medicaid. Inpatient and 
skilled nursing facility (SNF) records were drawn from Medicare Part A. Medication 





and Characteristics Files. The Minimum Data Set (MDS) 3.0, comprised of national data 
collected through mandatory assessments, provided information on SNF and long-stay 
nursing home residents in Medicare/Medicaid certified nursing homes. The MDS 3.0 data 
has been described in detail and validated previously.65-67 The University of 
Massachusetts Medical School Institutional Review Board approved this study 
(H00015376). 
Study Design 
A retrospective cohort study with an active comparator new-user design compared 
nursing home residents initiating apixaban, rivaroxaban, or dabigatran to warfarin 
initiators during the period 07/01/2011 to 12/31/2016. Indexing of new DOAC users 
began in the month following marketing approval for apixaban (12/2012) and 
rivaroxaban (11/2011). Follow-up continued until occurrence of a study outcome, 
anticoagulant discontinuation (a treatment gap of >14 days), anticoagulant switch, end of 
Medicare Parts A, B, and D fee-for-service enrollment, or end of the study period 
(12/31/2016).  
Source Population 
The source population included residents of US nursing homes >65 years of age 
and diagnosed with non-valvular atrial fibrillation who newly initiated a DOAC or 
warfarin. Included residents had >6 months of pre-index Medicare fee-for-service 
enrollment and at least one diagnosis for atrial fibrillation, atrial flutter, or dysrhythmia 
on Part A or MDS 3.0 records during the pre-index year (Table 4.1). Because 





in Part D data, we excluded residents in a hospital, SNF, or on hospice on the index date. 
We also excluded residents with another indication for oral anticoagulant initiation based 
on an inpatient diagnosis of venous thromboembolism (VTE), valvular disease, or total 
hip/knee replacement during the baseline 6 months (Table 4.1). Residents with cancer or 
in a coma were also excluded due to distinct considerations regarding benefits and risks 
of treatment for these patients.  
Anticoagulant Use 
We operationally defined anticoagulant use to allow evaluation of specific 
anticoagulants initiated (warfarin, apixaban, dabigatran, rivaroxaban) because of 
differences in pharmacology and evidence suggesting safety and effectiveness may vary 
among the DOACs. Edoxaban was not studied due to low utilization. New users were 
defined as residents initiating one of these medications, without prior use of an oral 
anticoagulant in the preceding six months. The date of the first oral anticoagulant 
dispensing was established as the index date. Following the index dispensing, an as-
treated approach was implemented using fill dates and number of days supplied from Part 
D claims to determine if residents remained exposed to the index medication on each day 
of follow-up. The end of treatment was assigned once the supply from the most recent 
medication fill was depleted and a gap in treatment of >14 days was observed, accounting 
for the potential for medication accumulation because of early fills and inpatient stays. 
Because DOACs are available in two dosages, we categorized residents as initiating 






Primary time-to-event outcomes included ischemic cerebrovascular event 
((ischemic stroke or transient ischemic attack (TIA)), intracranial or extracranial 
bleeding, and a composite net clinical benefit outcome comprised of ischemic stroke, 
TIA, intracranial bleeding, extracranial bleeding, venous thromboembolism (VTE), acute 
myocardial infarction (AMI), systemic embolism, and all-cause mortality. Each of the 
components of the net clinical benefit outcome, which was modeled after the net clinical 
benefit outcome from the RE-LY clinical trial,28 were evaluated as secondary outcomes. 
Clinical outcomes were operationalized from diagnoses on hospitalization records using 
previously validated ICD-9 code-based algorithms (Table 4.1),79,80,103,104 which were 
converted to ICD-10 using General Equivalence Mapping from the Centers for Medicare 
and Medicaid Services.128 For each outcome, time-to-event was calculated as number of 
days from index until an outcome or censoring event. All outcomes were evaluated for 
the maximum duration of follow-up available with our data. 
Covariates 
Covariates included sociodemographics, the CHA2DS2-VASc
81 and ATRIA82 risk 
scores and their components, hospitalizations, medication use, cognitive impairment, and 
functioning in activities of daily living (ADLs). Baseline hospitalizations for ischemic 
stroke or bleeding events were identified using the claims-based algorithms applied for 
outcome identification during the post-index period (Table 4.1).79,80 The total number of 
hospitalizations and the number of unique medications used during the pre-index 6 
months were summed. Polypharmacy has been linked to mortality risk.129 Residents were 





inflammatory drugs, statins, angiotensin converting enzyme inhibitors and angiotensin 
receptor blockers, selective serotonin reuptake inhibitors) associated with study 
outcomes85-86,105-108 if at least one Part D claim was present during the pre-index 6 
months. 
Comorbid clinical conditions were operationalized using information from MDS 
3.0 assessments with the exception of renal functioning, which was categorized as no 
impairment, chronic renal insufficiency without end-stage disease or dialysis,84 end-stage 
renal disease (MDS item I1500) without dialysis, and dialysis (MDS item O0100J2). 
Cognitive status, a risk factor for mortality,130 was categorized into no impairment, mild, 
moderate, and severe impairment using the MDS 3.0 Cognitive Function Scale.74 
Functional limitations in toileting, personal hygiene, locomotion, and eating were 
summarized using the ADL score (range 0-16 with higher scores indicating greater 
limitation).87 
Statistical Analysis 
We developed three separate cohorts for apixaban, dabigatran, rivaroxaban, 
respectively, using propensity score matching to develop comparable groups of DOAC 
and warfarin initiators. Each DOAC was matched separately because of differences in 
resident characteristics and temporal initiation patterns between DOACs. 
Frequencies and percentages for categorical variables and medians with first and 
third quartiles were summarized by medication before and after matching for each of the 
three study cohorts. The propensity score estimation approach included the above 





85-86,105-108,129-130  avoiding bias from inclusion of variables only associated with the 
exposure.131-133 Matching was performed within index year to account for secular trends. 
After matching, all characteristics with sufficient prevalence in the cohort (>5%) to 
represent potential confounding threats were well balanced (standardized difference 
<0.10).134 
Incidence rates were calculated for all primary and secondary outcomes. Cox 
proportional hazards models estimated cause-specific hazard ratios comparing each 
DOAC to warfarin. Dose was examined in combination with renal function as a source of 
potential heterogeneity. Prespecified analyses were performed within subgroups defined 
by DOAC dose alignment (or misalignment) with product labeling. Specifically, residents 
were classified as receiving supratherapeutic dosing (standard dose in the presence of an 
indication for dose reduction), aligned standard dosing, aligned low dosing, and 
subtherapeutic dosing (low dose in the absence of an indication for dose reduction). To 
evaluate potential selection bias in the early DOAC post-approval period, we conducted 
stratified analyses by time period (dichotomized as halves of the full study period). To 
examine the effects of the drug interaction between anticoagulants and antiplatelets, 
stratified analyses were performed among antiplatelet users and non-users. The 
proportional hazards assumption was evaluated graphically and satisfied for all models.  
Sensitivity analyses 
To examine residual confounding, hospitalizations for pneumonia and chronic 






Among 3,422 apixaban, 3,758 rivaroxaban, and 1289 dabigatran initiators, 84%, 
99%, and 100% were matched to warfarin initiators. 
Resident Characteristics 
Resident characteristics were summarized by treatment within matched cohorts 
(apixaban cohort n=5,762; dabigatran cohort n=2,578, and rivaroxaban cohort n=7,470; 
Table 4.2) and for the eligible population (n=21,346; Table 4.3). The median age was 83 
years in the dabigatran cohort and 84 in the rivaroxaban and apixaban cohorts. In all 
cohorts more than two-thirds of residents were dual Medicare-Medicaid enrollees. 
Warfarin and DOAC users within each cohort had median CHA2DS2-Vasc risk scores of 
5 (Q1 4, Q3 6) and ATRIA risk scores of 3 (Q1 3, Q3 6). The prevalence of renal 
impairment ranged from 29% in the dabigatran cohort to 40% in the apixaban cohort. 
Approximately one-eighth of DOAC users received standard dosages in the presence of 
an indication for dose reduction, while 34% of apixaban, 41% of dabigatran, and 56% of 
rivaroxaban users received low dosages without an indication for dose reduction.  
Follow-up 
The median duration of follow-up in the apixaban cohort was 137 days for 
apixaban and 124 days for warfarin users, during which time 663 events and 767 events 
occurred over 1,792 and 1,602 person-years, respectively. Median follow-up was 134 
days for dabigatran and 212 days for matched warfarin users, during which time 372 and 
571 events occurred during 1,153 and 1,384 person-years, respectively. Median follow-





users, during which time 1,049 and 1,223 events occurred over 2,710 and 2,722 person-
years, respectively. 
Apixaban versus Warfarin 
The crude incidence of ischemic stroke and TIA was 1.67 events per 100 person-
years among apixaban users and 0.94 events per 100 person-years among warfarin users 
(Table 4.4). Bleeding (intracranial and extracranial) rates were 4.35 and 6.74 events per 
100 person-years among apixaban and warfarin users, respectively. The combined rate of 
AMI, VTE, and systemic embolism was 2.29 and 3.37 events per 100 person-years 
among apixaban and warfarin users.  
Hazard ratios comparing apixaban to warfarin were 1.86 (95% CI: 1.00-3.45) for 
ischemic stroke/TIA and 0.66 (0.49-0.88) for bleeding (Table 4.5). Mortality was more 
than six times as numerous as any of the other outcomes and comprised more than 83% 
of the composite outcomes, and consequently, the mortality hazard ratio closely 
resembled the composite outcome hazard ratio (HR: 0.79; 95% CI: 0.71-0.88). Estimates 
for individual clinical components were directionally aligned with composite outcomes, 
with modest variation in the strength of associations (Table 4.6).  
In analyses exploring heterogeneity by alignment of dosing with labeling 
recommendations, hazard ratios comparing bleeding rates between apixaban and warfarin 
consistently favored apixaban except in the subgroup receiving standard dose apixaban in 
the presence of an indication for dose reduction (HR: 1.87; 95% CI: 0.75-4.63) (Table 
4.5). Although point estimates for ischemic stroke/TIA consistently favored warfarin, the 





lower among aligned standard dose apixaban users (HR: 0.54; 0.44-0.65) and among low 
dose apixaban users without an indication for dose reduction (HR: 0.68; 0.53-0.86), but 
mortality rates were comparable to warfarin in the other dosing subgroups.  
In analyses by index year (Table 4.7), point estimates favored apixaban for all 
study outcomes among those initiating anticoagulants in 2013-2014. Associations were 
attenuated, or in the case of ischemic stroke/TIA, reversed (2013-2014 HR: 0.89, 95% 
CI: 0.31-2.55; 2015-2016 HR: 2.71; 95% CI: 01.21-6.06) among those initiating during 
2015-2016. Stratified analyses by antiplatelet use suggested heterogeneity may exist in 
the treatment-outcome association between those using and not using antiplatelets (Table 
4.8). Associations between treatment and the falsification outcomes pneumonia and 
COPD were not indicative of strong residual cofounding (Table 4.9). 
Dabigatran versus Warfarin 
The crude incidence of ischemic stroke/TIA among dabigatran and warfarin users 
was 1.73 and 1.88 events per 100 person-years, respectively. Bleeding rates per 100 
person-years were 6.07 (dabigatran) and 5.28 (warfarin). Hazard ratios did not suggest a 
meaningful difference in the rate of either outcome. As in the other DOAC cohorts, 
mortality was the most common outcome. Mortality (HR: 0.68; 95% CI: 0.59-0.79) and 
composite event rates (HR: 0.76; 95% CI: 0.67-0.87) were lower among dabigatran users. 
Although confidence intervals were wide, point estimates for ischemic stroke/TIA 
favored dabigatran across dosing subgroups with the exception of those receiving less 
than standard dosing without an indication (HR: 2.50; 95% CI: 0.75-8.33). Bleeding rates 





exception of the group receiving standard doses in the presence of an indication for dose 
reduction (HR: 1.80; 95% CI: 0.77-4.20). Mortality and composite rates were lower 
among dabigatran users in each dosing subgroup except for those receiving standard 
doses in the presence of an indication for dose reduction, among whom mortality and 
composite rates were similar for dabigatran and warfarin users. 
Rivaroxaban versus Warfarin 
The incidence of ischemic stroke/TIA was 1.84 events per 100 person-years 
among rivaroxaban and 1.69 events per 100 person-years among warfarin users. Bleeding 
rates were 6.46 (rivaroxaban) and 6.02 (warfarin) events per 100 person-years. 
Intracranial hemorrhage, (HR: 0.42; 95% CI: 0.19-0.90), mortality (HR: 0.79; 95% 0.72-
0.87) and composite event rates (HR: 0.86; 95% CI: 0.79-0.94) were lower among 
rivaroxaban users. As in the apixaban cohort, heterogeneity in the incidence of ischemic 
and bleeding events were observed between warfarin initiators in the first (2011-2013 
ischemic stroke/TIA: 2.46/100 PYs; bleeding: 4.39/100 PYs) and second (2014-2016 
ischemic stroke/TIA: 1.29/100 PYs; bleeding: 6.88/100 PYs) halves of the study period 
(Table 4.7). 
In subgroup analyses by dose and indication, mortality and composite event rates 
were lower among standard dose rivaroxaban users but not among low dose rivaroxaban 
users, regardless of indication. Bleeding rates were higher among low dose rivaroxaban 
users with an indication for dose reduction (HR: 1.77; 95% CI: 1.01-3.09), while 
ischemic stroke/TIA rates were higher among low dose rivaroxaban users without an 






In this national study of US nursing home residents, apixaban, rivaroxaban, and 
dabigatran were each associated with lower mortality and composite outcome rates 
compared with warfarin. Treatment-outcome associations for clinical endpoints varied 
between DOACs. Ischemic cerebrovascular event rates and bleeding rates among 
rivaroxaban and dabigatran users were comparable to event rates among warfarin users. 
Apixaban users experienced higher rates of ischemic cerebrovascular events and a lower 
rate of bleeding events compared with warfarin users. The interpretation of these findings 
was complicated by high mortality rates and heterogeneity in estimates across dosing 
subgroups and over the course of the study period. In aggregate, the results of this first 
investigation of the comparative effectiveness of the DOACs versus warfarin among 
nursing home residents suggested that DOACs are being used with equal or greater 
benefit than warfarin.  
In the BAFTA trial,59 ischemic or unknown stroke occurred at a rate of 1.2 events 
per 100 person-years among warfarin users compared with 3.0 events per 100 person-
years among aspirin users, with no differences observed in major hemorrhage rates.59 
Despite the large burden of vascular risk factors in the nursing home population, we 
observed ischemic stroke incidence rates generally consistent with anticoagulants in 
BAFTA and the major DOAC clinical trials.28-29,31,59 Rates of major bleeding, which 
carries a more stringent definition than our outcome of bleeding related hospitalization, 
ranged from 2.1 to 3.6 for the DOACs and 3.1 to 3.4 for warfarin across trials.28-29,31 





clinical trials28-29,31,59 were one-fifth to one-third the mortality rates in the nursing home 
setting. Consistent with our findings, all-cause mortality rates were lower for the DOACs 
versus warfarin in the DOAC trial28-29,31 and in the Medicare population.97 
Utilization of low and misaligned DOAC dosages was more prevalent in the 
nursing home than in community-based cohorts.92,137 Although some fraction of such 
dosing is potentially inappropriate, deviation from labeled dosing is also likely to occur 
as a consequence of shared decision-making between clinicians, caregivers, and patients 
who together consider the preferences and characteristics of an individual (as 
recommended in clinical guidelines24) alongside often inadequate information on the 
absolute and relative risks of alternative treatment strategies for a specific individual. 
Dose-specific evidence on the safety and effectiveness of low DOAC dosages is limited, 
particularly among high-risk older adults. The 75 mg dabigatran dose, which is only 
marketed in the US, was not studied in the RE-LY clinical trial.28 Although the 15mg 
rivaroxaban dose was used for patients with a renal indication in the ROCKET-AF trial,31 
only pooled analyses were reported with the standard dose. In the ARISTOTLE trial, 
estimates for the 2.5mg apixaban dose were consistent with the standard 5 mg dose, 
although the sample size was small (n=831).29  
Our findings were consistent with earlier research linking off-label dosing with 
ischemic stroke and bleeding risk. Among community-dwelling patients with private 
insurance or Medicare Advantage, ischemic stroke rates were higher among low dose 
apixaban users with and without a renal indication.92 For apixaban users considered 





five times greater than among apixaban 5 mg users, with similar bleeding rates.92 In the 
same study, a pooled analysis of all 3 DOACs indicated that use of standard dosing in 
patients with a renal indication was associated with a more than twofold higher risk of 
major bleeding without a countervailing benefit for stroke risk.92 Another study of 
community-dwelling ORBIT-AF registry members reported similar off-label dosing-
outcome associations.137 In our study, low dose apixaban and rivaroxaban users had 
higher rates of ischemic stroke/TIA with or without an indication for dose reduction, 
while underdosing (but not low dosing by indication) of dabigatran was associated with 
elevated ischemic stroke/TIA risk. The increased bleeding rate among aligned low dose 
rivaroxaban (15mg dose is 75% of the standard dose) but not under-dosed rivaroxaban 
users may stem from the 36% of under-dosed residents using the off-label rivaroxaban 
10mg (50% of standard) dosage. 
Although we applied a new-user active comparator design to mitigate selection 
biases often present in non-user or prevalent user comparisons, further research is needed 
to inform the decision to initiate, switch, or discontinue an anticoagulant, particularly for 
older adults with limited life expectancy. Differences in market entry dates for apixaban 
(12/2012), dabigatran (10/2010), and rivaroxaban (11/2011) meant that the warfarin 
comparator group varied between DOACs. The recency of DOAC approval also 
introduced the potential for channeling bias during the early post-approval period (i.e., a 
form of selection bias where the types of patients prescribed a newly marketed drug have 
a different prognosis than the types of patients prescribed an established drug with the 





we sought to identify a comparison group that reflected the prevailing real-world 
treatment conditions facing clinicians during a given time period. Cost is one potential 
mechanism through which channeling bias may operate. Multiple studies in community 
dwelling populations have found higher socioeconomic status to be associated with 
higher DOAC use after accounting for other factors (including prescriber specialty), 
suggesting the cost of newer (branded) DOACs may have deterred utilization for certain 
patients of lower socioeconomic status. The effects of cost on treatment selection was 
less of a concern in our study because more than two-thirds of our study population was 
dually Medicare-Medicaid enrolled (and had copay assistance), including similar 
proportions of residents in DOAC and warfarin treated groups.  
Changes in ischemic and bleeding outcomes among residents initiating warfarin at 
different time points (i.e., before and after DOACs were commonly used in nursing 
homes)99 suggests the quality of warfarin therapy, other delivery system factors, or 
patient characteristics may have been shifting during the study period. Although we lack 
laboratory values on renal functioning and time in therapeutic range, rather than bias our 
results, the observed changes over time represent the reality of changing treatment 
patterns with a highly individualized and oversight-intensive medication in the face of the 
entrance of alternative therapeutic options. The balance in observed characteristics within 
the matched cohorts and the absence of clear relationships between treatment group and 
falsification outcomes attenuates concerns of unmeasured confounding and lends support 
to the potential for contributions of health system factors such as warfarin dose titration 





who died during follow-up, introducing the potential for under-detection of fatal clinical 
events for those residents who experienced a study outcome and were not transported to 
the hospital. Consequently, incidence rates for clinical events were likely underestimated. 
Although deaths related to bleeding and embolic events comprised an unknown fraction 
of all deaths occurring in the nursing home, the consistent survival advantage for all 3 of 
the DOACs suggests the incidence of fatal clinical events among DOAC users may have 
been lower compared with warfarin users. 
Conclusions 
As the first study to investigate outcomes of anticoagulation in the nursing home 
setting in a contemporary post-DOAC period, our findings are foundational and provide 
initial guidance for clinical decision-makers caring for older, institutionalized 
populations. Ultimately, although comparative safety and effectiveness estimates varied 
by drug and dose, our findings of very low ischemic stroke rates without excessive 
bleeding reinforces the clinical utility of anticoagulation with either medication class for 
this older population at high risk of vascular and bleeding events. 
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Table 4.1. ICD-9 and ICD-10 Code Based Definitions Applied to Medicare Part A 
Claims to Identify Specific Conditions 
Clinical Condition ICD-9 CM Codes ICD-10 CM Codes* 
Atrial 
fibrillation/flutter† 
42731, 42732 I480, I481, I482, I483, I484, 
I4891, I4892 
Valvular disease‡ 33400, 99602, 99661, 
V433, V422, 3979, 
3971, 3970, 3969, 
3968, 3963, 3962, 
3961, 3960, 3959, 
3952, 3951, 3950, 
3949, 3942, 3941, 
3940, 7467, 7466, 
7465, 7464, 7463, 
7462, 7461, 74609, 
74602, 74601, 74600, 
4243, 4242, 4241, 
4240 
I050, I051, I052, I058, I059, 
I069, I068, I062, I061, I060, 
I080, I088, I089, I0989, I091, 
I083, I082, I081, I079, I078, 
I072, I071, I070, A1884, I340. 
I341, I342, I348, I349, I350, 
I351, I352, I358, I359, I360, 
I361, I362, I368, I370, I371, 
I372, I378, I379, I38, I39, 
M3211, Q209, Q220 Q221, 
Q222, Q223, Q224, Q225, Q226, 
Q228, Q229, Q230, Q231, Q232, 
Q234, Z953, Z952, Z954, 
T8201XA, T8201XD, T8201XS, 
T8202XA, T8202XD, T8202XS, 
T8203XA, T8203XD, T8203XS, 
T8209XA, T8209XD, T8209XS, 
T826XXA, T826XXD, 
T826XXS,  
Ischemic stroke§ 43301, 43311, 43321, 
43331, 43381, 43391, 
43401, 43411, 43491, 
436 
I6302, I6312, I6322, I63239, 
I63232, I63231, I63139, I63132, 
I63131, I63039, I63032, I63031, 
I63011, I63012, I63019, I63111, 
I63112, I63119, I63211, I63212, 
I63219, I6359, I6319, I6309, 
I6329, I6320, I6310, I6300, 
I6330, I63311, I63312, I63319, 
I63321, I63322, I63329, I63331, 
I63332, I63339, I63341, I63342, 
I63349, I6339, I636, I6349, 
I63449, I63442, I63441, I63439, 
I69432, I69431, I63429, I63422, 
I63421, I63419, I63412, I63411, 
I63430, I6350, I63511, I63512, 
I63519, I63521, I63529, I63531, 
I63532, I63539, I63541, I63542, 







430, 431, 4320, 4321, 
4329 
I609, I608, I607, I606, I6052, 
I6051, I6050, I604, I6032, I6031, 
I6030, I6022, I6021, I6020, 
I6012, I6011, I6010, I6002, 
I6001, I6000, I610, I611, I612, 
I613, I614, I615, I616, I618, 




In primary position 
alone: 
5310, 5312, 5314, 
5316, 5320, 5322, 
5324, 5326, 5330, 
5332, 5334, 5336, 
5340, 5342, 5344, 
5346, 53501, 53511, 
53521, 53531, 53541, 
53551, 53561, 53783, 
4560, 45620, 5307, 
53082, 5780, 4552, 
4555, 4558, 56202, 
56203, 56212, 56213, 
56881, 5693, 56985, 
5781, 5789, 59381, 
5997, 6238, 6262, 
6266, 4230, 4590, 
56881, 7191, 7847, 
7848, 7863 
 
In primary position, 
with above code in 
secondary position: 
5311, 5313, 5315, 
5317, 5319, 5321, 
5323, 5325, 5327, 
5329, 5331, 5333, 
5335, 5337, 5339, 
5341, 5343, 5345, 
5347, 5349, 53500, 
53510, 53520, 53530, 
53540, 53550, 53560, 
455, 56200, 56201, 
56210, 56211, 5301, 
In primary position alone: 
K252, K254, K256, K260, K262, 
K264, K266, K270, K272, K274, 
K276, K280, K282, K284, K286, 
K2901, K2931, K2941, K2951, 
K2961, K2921, K2971, K2981, 
K2991, K31811, I8501, I8511, 
K226, K228, K920, K648, K643, 
K642, K641 K640, K5711, 
K5751, K5753, K5741, K5713, 
K5701, K5791, K5731, K5793, 
K5781, K5733, K5721, K661, 
K625, K5521, K921, K922, 
N280, R310, R311, R312, R319, 
N898, N920, N921, I312, R58, 
M2500, M25011, M25012, 
M25019, M25021, M25022, 
M25029, M25031, M25032, 
M25039, M25041, M25042, 
M25049, M25051, M25052, 
M25059, M25061, M25062, 
M25069, M25071, M25072, 
M25073, M25074, M25075, 
M25076, M2508, R040, R041, 
R042, R0481, R0489, R049 
 
In primary position, with above 
code in secondary position: 
K251, K253, K255, K257, K259, 
K261, K263, K265, K267, K269, 
K271, K273, K275, K277, K279, 
K281, K283, K285, K287, K289, 
K2900, K2930, K2960, K2920, 
K2930, K2970, K2980, K640, 
K641, K642, K643, K644, K645, 





2800, 2851, 2859, 
79092 
K5752, K5740, K5712, K5700, 
K5730, K5790, K5792, K5780, 
K5732, K5720, K210, K209, 




582, 583, 585, 586, 
587 
M3218, M3214, M3504, N050, 
N051, N052, N053, N054, N055, 
N056, N057, N058, N059, N060, 
N061, N062, N063, N064, N065, 
N066, N067, N068, N069, N070, 
N071, N072, N073, N074, N075, 
N076, N077, N078, N079, N08, 
N140, N142, N144, N150, N158, 
N159, N171, N16, N170, N172, 
N178, N179, N181, N182, N183, 




41001, 41011, 41021, 
41031, 41041, 41051, 
41061, 41071, 41081, 
41091 
I2109, I220, I2102, I2101, I2119, 
I221, I2111, I228, I2129, I214, 
I2121, I222, I229, I213 
Venous 
thromboembolism§§ 
41511, 41519, 45111, 
45119, 4512, 4519, 
4531, 4532, 4534, 
45341, 45342, 4538, 
4539 
I803, I809, I821, I82220, I82401, 
I82402, I82403, I82409, I84211, 
I82412, I82413, I82419, I82421, 
I82422, I82423, I82429, I82431, 
I82432, I82433, I82439, I82441, 
I82442, I82443, I82449, I82491, 
I82492, I82493, I82499, I824Y1, 
I824Y2, I824Y3, I824Y9, 
I824Z1, I824Z2, I824Z3, 
I824Z9, I82210, I82290, I82601, 
I82602, I82603, I82609, I82611, 
I82612, I82613, I82619, I82621, 
I82622, I82629, I82890, I82891, 
I8290, I82A11, I82A12, I82A13, 
I82A19, I82A21, I82A22, 
I82A23, I82A29, I82B11, 
I82B12, I82B13I82B13, I82B19, 
I82B21, I82B22, I82B23, 
I82B29, I82C11, I82C12, 
I82C13, I82C19 
Systemic embolism‡ 444, 445 I74 
Pneumonia*** 480, 481, 482, 485, 
486, 4870 
J120, J121, J122, J123, J1281, 





J150, J151, J152, J15211, 
J15212, J1529, J153, J154, J155, 
J156, J158, J159, J180, J188, 




In primary position 
alone: 
49121, 49122, 4918, 
4919 4928, 49320, 
49321, 49322, 496 
 
In primary position, 
with above code in 
secondary position: 
51881, 51882, 51884, 
7991 
 
In primary position alone: 
J441J J440, J418, J42, J439, 
J438, J432, J431, J430, J449 
 
In primary position, with above 
code in secondary position: 
J9600, J9601, J9602, J9690, 
J9691, J9692, J80, J9620, 9621, 
J9622, R092 
*ICD-9 CM code based algorithms were converted to ICD-10 CM codes using the 
2016 General Equivalence Mappings available from the Centers for Medicare and 
Medicaid Services at https://www.cms.gov/Medicare/Coding/ICD10/2016-ICD-10-
CM-and-GEMs.html 
 
†Jensen PN, Johnson K, Floyd J, Heckbert SR, Carnahan R, Dublin S. A systematic 
review of validated methods for identifying atrial fibrillation using 
administrative data. Pharmacoepidemiol Drug Saf. 2012 Jan;21 Suppl 1:141-7. 
 
‡Coleman CI, Peacock WF, Bunz TJ, Alberts MJ. Effectiveness and Safety of 
Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients with Nonvalvular 
Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack. Stroke. 
2017;48(8):2142-2149. 
 
§Kumamaru H, Judd SE, Curtis JR, Ramachandran R, Hardy NC, Rhodes JD, Safford 
MM, Kissela BM, Howard G, Jalbert JJ, Brott TG, Setoguchi S. Validity of claims-
based stroke algorithms in contemporary medicare data: reasons for geographic and 
racial differences in stroke (REGARDS) study linked with medicare claims. Circ 
Cardiovasc Qual Outcomes. 2014;7:611–9. 
 
**Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray WA. An 
automated database case definition for serious bleeding related to oral anticoagulant 
use. 2011;(March):560-566.  
 
††Winkelmayer WC, Schneeweiss S, Mogun H, Patrick AR, Avorn J, Solomon DH. 
Identification of individuals with CKD from medicare claims data: A validation study. 






‡‡Kiyota Y, Schneeweiss S, Glynn RJ, Cannuscio CC, Avorn J, Solomon DH. 
Accuracy of medicare claims-based diagnosis of acute myocardial infarction: 
Estimating positive predictive value on the basis of review of hospital records. Am 
Heart J. 2004;148(1):99-104.  
 
§§White RH, Garcia M, Sadeghi B, et al. Evaluation of the predictive value of ICD-9-
CM coded administrative data for venous thromboembolism in the United States. 
Thromb Res. 2010;126(1):61-67. 
 
***Lindenauer PK, Normand SLT, Drye EE, et al. Development, validation, and results 
of a measure of 30-day readmission following hospitalization for pneumonia. J Hosp 
Med. 2011;6(3):142-150. 
 
†††Yale New Haven Health Services Corporation/Center for Outcomes Research & 
Evaluation. 2014 Measures updates and specifications report hospital-level 30-day 
risk-standardized readmission measures. 2014. Available at: 
http://altarum.org/sites/default/files/uploaded-publicationfiles/ 





Table 4.2. Characteristics of Residents Treated with Apixaban, Dabigatran, Rivaroxaban, and Matched 
Warfarin Users 













Demographics       
Age in years, 
median (Q1, Q3) 
84 (77, 89) 84 (76, 89) 83 (77, 89) 83 (77, 89) 84 (77, 89) 84 (77, 89) 
Women, % 68.5 67.8 67.2 69.7 69.3 68.2 
Enrolled in 
Medicaid, % 
68.5 70.3 74.9 72.2 72.1 71.8 
Hospital admissions in prior year, % 
Number of hospitalizations, % 
1 36.8 37.9 33.4 31.3 36.1 36.4 
2-3+ 33.4 32.7 30.1 31.0 30.6 28.6 
Ischemic stroke 12.7 12.8 12.6 11.4 10.6 10.6 
Extracranial or 
intracranial bleed 
1.8 1.8 1.5 1.8 
1.3 1.5 
Time since first 
observed nursing 
















median (Q1, Q3) 
21 (13, 31) 22 (13, 32) 17 (11, 25) 16 (10, 24) 21 (13, 30) 21 (13, 31) 
DOAC dose, %       







    
  
NSAID 35.5 36.4 28.2 25.6 35.1 36.7 
Antiplatelet 25.0 23.7 23.0 22.7 22.7 22.2 
Statin 59.5 60.5 49.4 45.5 54.9 55.5 
SSRI 47.2 48.2 45.6 46.2 48.9 49.3 
ACE inhibitor or 
ARB 




    
  
Diabetes 39.5 37.5 37.2 35.7 35.3 35.7 
Heart failure 35.8 34.8 36.9 36.5 33.4 33.6 
Hypertension 85.9 85.7 84.2 83.4 83.9 84.0 
Coronary artery 
disease 
29.9 27.5 29.3 28.1 
16.4 25.6 
Anemia 29.5 28.8 27.4 26.4 28.8 29.4 
Fall history 16.4 17.8 17.1 15.4 19.0 19.7 
Stroke 22.0 21.4 24.7 23.5 22.5 21.7 
Renal impairment       
Chronic renal 
insufficiency 




13.7 13.8 11.5 12.7 
11.5 12.5 





















5 (4, 6) 5 (4, 6) 5 (4, 6) 5 (4, 6) 5 (4, 6) 5 (4, 6) 
ATRIA Bleeding 
Risk Score,   % 
3 (3, 6) 3 (3, 6) 3 (3, 6) 3 (3, 6) 3 (3, 6) 3 (3, 6) 
Cognitive skills, 
% 
    
  




32.8 33.0 33.1 34.7 
37.0 37.0 
ADL score (0-16),† 
median (Q1, Q3) 
10 (7, 11) 10 (7, 11) 9 (6, 11) 9 (7, 11) 10 (7, 12) 10 (8,12) 
Life expectancy 
>6months 
99.5 99.7 >99.5 >99.5 
>99.0 >99.0 
*Any Part D claim during the 12-month period 
†Higher scores indicate greater limitation in ADLs 
Abbreviations: activities of daily living (ADLs), non-steroidal anti-inflammatory drugs (NSAID), selective 
serotonin reuptake inhibitor (SSRI), angiotensin converting enzyme (ACE), angiotensin receptor blocker (ARB), 




Table 4.3. Characteristics of Residents Treated with Apixaban, Dabigatran, 









Demographics     
Age in years, 
median (Q1, Q3) 
84 (77, 89) 83 (77, 89) 84 (76, 89) 84 (77, 89) 
Women, % 69.0 67.2 69.2 66.7 
Non-Hispanic 
white 
84.5 86.1 85.1 84.7 
Enrolled in 
Medicaid, % 
68.5 74.9 71.8 72.4 
Hospital admissions in 
prior year, % 
    
Number of 
hospitalizations, % 
    
1 39.0 33.4 36.3 33.4 
2-3+ 34.2 30.1 30.6 30.4 
Ischemic stroke 12.4 12.6 10.5 11.7 
Extracranial or 
intracranial bleed 
1.9 1.5 1.6 1.9 
Time since nursing 











median (Q1, Q3) 
22 (14, 33) 17 (11, 25) 21 (13, 30) 
17 (11, 
25) 
DOAC dose, %     
Less than standard 50.0 42.0 59.3 NA 
Select Medications,* %     
NSAID 38.8 28.2 35.4 26.0 
Antiplatelet 27.1 23.1 22.7 19.2 
Statin 61.8 49.3 54.9 49.3 
SSRI 48.4 45.6 49.1 43.8 
ACE inhibitor or 
ARB 
64.7 59.5 61.0 53.9 
Select Comorbidities, %     
Diabetes 39.1 37.1 35.2 38.3 
Heart failure 35.8 36.8 33.2 35.7 
Hypertension 86.3 84.2 83.9 83.6 
Coronary artery 
disease 
29.7 29.4 26.4 28.6 
Anemia 27.9 27.5 28.9 32.3 





Stroke 20.7 24.8 22.4 24.4 
Renal impairment     
Chronic renal 
insufficiency 














5 (4, 6) 5 (4, 6) 5 (4, 6) 5 (4, 6) 
ATRIA Bleeding 
Risk Score,   % 
3 (3, 6) 3 (3, 6) 3 (3, 6) 3 (3, 6) 
Cognitive skills, %     
Mildly impaired 26.4 27.6 26.6 25.7 
Moderately to 
severely impaired 
31.5 33.1 36.8 36.0 
ADL score (0-16), † 
median (Q1, Q3) 
10 (7, 11) 9 (6, 11) 10 (7, 12) 10 (8, 12) 
*Any Part D claim during the 12-month period 
†Higher scores indicate greater limitation in ADLs 
Abbreviations: activities of daily living (ADLs), non-steroidal anti-inflammatory 
drugs (NSAID), selective serotonin reuptake inhibitor (SSRI), angiotensin converting 
enzyme (ACE), angiotensin receptor blocker (ARB), data use agreement (DUA), 






Table 4.4. Number of Events and Incidence Rates by Anticoagulant in Matched Cohorts of DOAC 









Rate Difference (95% CI) 




Apixaban vs. Warfarin 
Ischemic 
stroke/TIA 
30 1.67 15 0.94 0.73 (-0.03 to 1.49) 
Ischemic 
stroke 
24 1.34 13 0.81 0.53 (-0.16 to 1.22) 
Bleeding 78 4.35 108 6.74 -2.39 (-3.99 to -0.79) 
AMI/VTE/SE 41 2.29 54 3.37 -1.08 (-2.22 to 0.06) 
Mortality 554 30.7 645 40.0 -9.30 (-13.18 to -5.42) 





Dabigatran vs. Warfarin 
Ischemic 
stroke/TIA 
20 1.73 26 1.88 -0.15 (-1.20 to 0.90) 
Ischemic 
stroke 
14 1.21 18 1.30 -0.09 (-0.96 to 0.78) 
Bleeding 70 6.07 73 5.28 0.79 (-1.08 to 2.66) 
AMI/VTE/SE 25 2.17 44 3.18 -1.01 (-2.27 to 0.25) 
Mortality 283 24.3 496 35.09 -10.79 (-14.98 to -6.60) 
Composite 372 32.25 571 41.27 -9.02 (-13.73 to -4.31) 




Rivaroxaban vs. Warfarin 
Ischemic 
stroke/TIA 
50 1.84 46 1.69 0.15 (-0.56 to 0.86) 
Ischemic 
stroke 
37 1.36 36 1.32 0.04 (-0.58 to 0.66) 
Bleeding 175 6.46 164 6.02 0.44 (-0.89 to 1.77) 
AMI/VTE/SE 76 2.80 84 3.08 -0.28 (-1.19 to 0.63) 
Mortality 824 30.15 1052 38.07 -8.92 (-12.01 to -5.83) 
Composite 1049 38.70 1223 44.91 -6.21 (-9.65 to -2.77) 
Abbreviations:  transient ischemic attack (TIA), acute myocardial infarction (AMI), venous 




Table 4.5. Results of Cox Proportional Hazards Models Comparing DOAC and Warfarin Groups Overall 
and in Subgroups Defined by Alignment with Recommended Dosing 












Stroke/TIA 1.86 (1.00-3.45) 1.28 (0.29-5.70) 1.62 (0.60-4.39) 2.42 (0.85-6.86) 2.78 (0.29-26.71) 
Bleeding 0.66 (0.49- 0.88) 1.87 (0.75-4.63) 0.70 (0.43-1.15) 0.55 (0.33-0.93) 0.45 (0.23-0.87) 
AMI/VTE/SE 0.70 (0.46-1.05) 0.51 (0.15-1.76) 0.99 (0.51-1.90) 0.85 (0.43-1.71) 0.21 (0.06-0.75) 
Mortality 0.78 (0.70-0.88) 1.01 (0.73-1.39) 0.54 (0.44-0.65) 1.19 (0.97-1.47) 0.68 (0.53-0.86) 
Composite 0.79 (0.71-0.88) 1.08 (0.8-1.46) 0.59 (0.50-0.71) 1.09 (0.91-1.32) 0.66 (0.53-0.82) 












Stroke/TIA 0.92 (0.51-1.65) 0.70 (0.13-3.84) 0.59 (0.24-1.48) 0.63 (0.15-2.63) 2.50 (0.75-8.33) 
Bleeding 1.10 (0.80-1.53) 1.80 (0.77-4.2) 1.18 (0.71-1.95) 0.74 (0.32-1.73) 1.00 (0.53-1.89) 
AMI/VTE/SE 0.66 (0.40-1.09) 1.79 (0.54-5.98) 0.57 (0.29-1.16) 4.24 (0.47-39.98) 0.25 (0.07-0.85) 
Mortality 0.68 (0.59-0.79) 0.97 (0.67-1.41) 0.57 (0.45-0.71) 0.67 (0.46-0.97) 0.77 (0.59-1.01) 
Composite 0.76 (0.67-0.87) 1.15 (0.82-1.60) 0.65 (0.53-0.80) 0.73 (0.53-1.02) 0.82 (0.64-1.05) 

















Bleeding 1.07 (0.87-1.07) 1.08 (0.58-1.99) 0.95 (0.63-1.44) 1.77 (1.01-3.09) 0.99 (0.73-1.36) 
AMI/VTE/SE 0.91 (0.67-1.24) 0.70 (0.25-1.98) 1.02 (0.56-1.85) 0.77 (0.34-1.74) 0.96 (0.62-1.50) 
Mortality 0.79 (0.72-0.87) 0.75 (0.56-0.99) 0.63 (0.53-0.74) 1.04 (0.82-1.30) 0.87 (0.76-0.99) 
Composite 0.86 (0.79-0.94) 0.82 (0.64-1.06) 0.70 (0.60-0.82) 1.10 (0.89-1.35) 0.93 (0.82-1.05) 
*Receiving standard DOAC dosing in the presence of an indication for dose reduction. 
†Receiving standard DOAC dosing in the absence of an indication for dose reduction. 
‡Receiving an indicated renal dosage (apixaban 2.5 mg, dabigatran 75mg, rivaroxaban 15mg) in the presence of an 
indication for dose reduction. 
§Receiving a less than standard dose in the absence of an indication for dose reduction. Rivaroxaban 10 mg was 
considered underdosing in the presence and in the absence of renal impairment. 
Abbreviations: standard (std.), transient ischemic attack (TIA), acute myocardial infarction (AMI), venous 
thromboembolism (VTE), systemic embolism (SE), hazard ratio (HR), confidence interval (CI), direct acting oral 






Table 4.6. Results of Cox Proportional Hazards Models Comparing DOAC and Warfarin Groups on Component Endpoints of 
Composite Outcomes 

























24 (1.34) 13 (0.81) 
1.72  
(0.87-3.37) 
14 (1.21) 18 (1.30) 
0.93  
(0.47-1.88) 
37 (1.36) 36 (1.32) 
1.03  
(0.65-1.64) 
TIA* Sup. Sup. Sup. Sup. Sup. Sup. Sup. Sup. Sup. 
Extracranial 
bleeding 
69 (3.85) 93 (5.80) 
0.68  
(0.50-0.92) 





















         
AMI 26 (1.45) 27 (1.68) 
0.86  
(0.50-1.48) 
17 (1.47) 26 (1.88) 
0.78  
(0.42-1.44) 
39 (1.44) 42 (1.54) 
0.94  
(0.61-1.45) 
VTE* 14 (0.78) 25 (1.56) 
0.53  
(0.28-1.02) 
Sup. Sup. 0.45  
(0.19-1.08) 
31 (1.14) 37 (1.36) 
0.84  
(0.53-1.36) 
SE1 Sup. Sup. Sup. Sup. Sup. Sup. Sup. Sup. Sup. 
*Cell sizes suppressed so that no cell was <11 per data use agreement 
Abbreviations:  transient ischemic attack (TIA), acute myocardial infarction (AMI), venous thromboembolism (VTE), systemic embolism (SE), 







Table 4.7. Incidence Rates and Results of Cox Proportional Hazards Models Comparing DOAC and 
Warfarin Groups Overall and by Time Period 
Apixaban versus Warfarin 












 HR (95% CI) 
# Events (rate 
per 100 PYs) 
# Events (rate 
per 100 PYs) 
HR (95% 
CI) 
# Events (rate 
per 100 PYs) 
# Events 
(rate per 100 
PYs) 































407 (37.29) 468 (39.60) 
0.81  
(0.71-0.93) 






495 (27.58) 551 (30.70) 
0.84  
(0.74-0.95) 
168 (27.38) 216 (41.86) 
0.67  
(0.55-0.82) 
Dabigatran versus Warfarin 












 HR (95% CI) 
# Events (rate 
per 100 PYs) 
# Events (rate 
per 100 PYs) 
HR (95% 
CI) 
# Events (rate 
per 100 PYs) 
# Events 
(rate per 100 
PYs) 














16 (6.19) 17 (6.66) 
0.93  
(0.47-1.84) 






16 (1.79) 31 (2.74) 
0.69  
(0.29-1.61) 






212 (23.48) 398 (34.42) 
0.71 (0.53-
0.97 






280 (31.28) 454 (40.24) 
0.78  
(0.59-1.02) 
92 (35.57) 117 (45.83) 
0.76  
(0.65-0.88) 
Rivaroxaban versus Warfarin 












 HR (95% CI) 
# Events (rate 
per 100 PYs) 
# Events (rate 
per 100 PYs) 
HR (95% 
CI) 
# Events (rate 
per 100 PYs) 
# Events 
(rate per 100 
PYs) 




34 (1.89) 23 (1.29) 
1.48  
(0.87-2.51) 






118 (6.58) 123 (6.88) 
0.96  
(0.74-1.23) 






62 (3.46) 56 (3.13) 
1.10  
(0.77-1.58) 






563 (31.17) 709 (39.15) 
0.80  
(0.71-0.89) 






725 (40.40) 830 (46.39) 
0.87  
(0.79-0.96) 
324 (35.36) 393 (42.08) 
0.84  
(0.73-0.97) 
*Cell sizes suppressed so that no cell was <11 per data use agreement 
Abbreviations:  transient ischemic attack (TIA), acute myocardial infarction (AMI), venous thromboembolism (VTE), systemic embolism 




Table 4.8. Results of Cox Proportional Hazards Models Comparing DOAC and 
Warfarin Groups Overall and within Strata of Antiplatelet Users and Non-
Users 
 Overall Antiplatelet Use No Antiplatelet Use 
 HR (95% CI) HR (95% CI) HR (95% CI) 
 Apixaban versus Warfarin 
Stroke/TIA 1.86 (1.00-3.45) 0.93 (0.31-2.76) 2.48 (1.15-5.37) 
Bleeding 0.66 (0.49- 0.88) 0.30 (0.16-0.56) 0.85 (0.61-1.19) 
AMI/VTE/SE 0.70 (0.46-1.05) 0.58 (0.28-1.18) 0.74 (0.45-1.22) 
Mortality 0.78 (0.70-0.88) 0.85 (0.68-1.07) 0.75 (0.66-0.86) 
Composite 0.79 (0.71-0.88) 0.75 (0.62-0.92) 0.80 (0.70-0.90) 
 Dabigatran versus Warfarin 
Stroke/TIA 0.92 (0.51-1.65) 0.74 (0.26-2.07) 1.01 (0.50-2.05) 
Bleeding 1.10 (0.80-1.53) 1.24 (0.86-1.78) 0.67 (0.31-1.48) 
AMI/VTE/SE 0.66 (0.40-1.09) 0.57 (0.24-1.33) 0.73 (0.40-1.33) 
Mortality 0.68 (0.59-0.79) 0.63 (0.46-0.86) 0.70 (0.59-0.82) 
Composite 0.76 (0.67-0.87) 0.68 (0.52-0.90) 0.79 (0.68-0.92) 
 Rivaroxaban versus Warfarin 
Stroke/TIA 1.09 (0.73-1.63) 0.94 (0.45-1.96) 1.15 (0.72-1.85) 
Bleeding 1.07 (0.87-1.07) 0.96 (0.65-1.42) 1.11 (0.86-1.43) 
AMI/VTE/SE 0.91 (0.67-1.24) 0.95 (0.56-1.62) 0.88 (0.60-1.29) 
Mortality 0.79 (0.72-0.87) 0.83 (0.69-1.01) 0.78 (0.70-0.87) 
Composite 0.86 (0.79-0.94) 0.89 (0.76-1.06) 0.85 (0.77-0.93) 
Abbreviations: transient ischemic attack (TIA), acute myocardial infarction (AMI), 
venous thromboembolism (VTE), systemic embolism (SE), hazard ratio (HR), 







Table 4.9. Results of Cox Proportional Hazards Models Comparing DOAC and 








 HR (95% CI) HR (95% CI) HR (95% CI) 
Pneumonia1 0.92 (0.70-1.22) 1.15 (0.84-1.56) 1.24 (0.99-1.54) 
1st half of study 
period 
1.02 (0.63-1.63) 1.18 (0.86 -1.63) 1.33 (1.01-1.74) 
2nd half of study 
period 
0.88 (0.62-1.23) 0.85 (0.28-2.51) 1.10 (0.76-1.58) 
COPD2 0.88 (0.56-1.37) 0.97 (0.61-1.52 1.09 (0.78-1.52) 
1st half of study 
period 
0.69 (0.27-1.74) 1.12 (0.68-1.85) 0.72 (0.40-1.32) 
2nd half of study 
period 
0.95 (0.57-1.58) 0.54 (0.18-1.61) 1.32 (0.88-1.98) 
Abbreviations: chronic obstructive pulmonary disease (COPD), hazard ratio (HR), 












Despite large randomized controlled trials demonstrating the effectiveness of 
available oral anticoagulants,28-31,59 the generalizability of this evidence to the nursing 
home population is impeded by profound differences in patient characteristics and goals 
of care for those living independently in the community versus those residing in long-
term care facilities. The historical warfarin centered treatment paradigm was ill-suited to 
the nursing home setting, particularly as it existed prior to modern quality improvement 
efforts.27,50-52 Most residents with atrial fibrillation did not receive warfarin,49 and those 
who were treated typically spent the majority of time outside of the therapeutic range,27 
increasing the risk for adverse events. Therefore, the objectives of this dissertation were 
to 1) modernize the clinical community’s understanding of the atrial fibrillation treatment 
landscape in nursing homes, 2) explore what characteristics and potentially modifiable 
factors are associated with anticoagulant use in nursing homes, and 3) develop the 
comparative effectiveness evidence necessary to inform anticoagulant selection for this 
population.  
In Aim 1, we established a contemporary understanding of anticoagulant 
utilization patterns by describing the prevalence of anticoagulant use, switching, and 
discontinuation. Analyses were performed in the full population, by medication class, and 
by medication. Simultaneously, we characterized the diffusion of a new class of oral 
anticoagulants into the nursing home setting longitudinally, a path that ultimately led to a 
new treatment paradigm in which the longtime mainstay of treatment (warfarin) 
continues to occupy a diminishing role in anticoagulation for nursing home residents with 





subsequently conducted in Aims 2 and 3. In Aim 1, we identified the relevant time period 
during which an increase in anticoagulant utilization in the nursing home occurred after 
DOACs became available, which informed the selection of the study period for Aim 2, 
where we confirmed that the increase in anticoagulant use observed was not caused by 
changes in resident characteristics. In Aim 1, we also discovered that the use of DOAC 
doses that were not aligned with approved dosing recommendations was highly prevalent, 
which led to the inclusion of stratified analyses comparing medication safety and 
effectiveness by alignment of dosing with labeling recommendations in Aim 3.  
The descriptive analyses in Aim 1 suggested resident factors such as cognitive 
impairment and recent clinical events (i.e., ischemic stroke, bleeding) were associated 
with anticoagulant use, but the multilevel multivariable modeling performed in Aim 2 
was critical for understanding what resident, facility, and county characteristics were 
associated with prescribing in the nursing home setting, and whether anticoagulant use 
varied across the United States. As expected, well-recognized clinical risk factors 
comprising risk scoring algorithms were important predictors of treatment. Considerable 
variation in anticoagulant use was observed between counties, both within and between 
states. Most notably, this large variation in prescribing was not explained by resident 
factors as would be expected in situations where adequate evidence exists and best 
practices have been disseminated and standardized. Instead, after accounting for resident 
factors, the amount of variation in anticoagulant use between counties increased. The 
relative contributions of shared decision-making, as is recommended, versus other less 





support) and minority populations, could not be disentangled with the available data. 
However, the magnitude of geographic variation and the disconnectedness from resident 
characteristics underscored the substantial need for safety and effectiveness information 
specific to anticoagulant use in the nursing home population. 
In Aim 3, we began to address this prominent gap in the evidence, a gap that will 
become increasingly conspicuous as the size of the nursing home population continues to 
increase. This evidence gap was two-fold; 1) among residents with atrial fibrillation there 
is a need to distinguish which residents should be treated, and 2) among those for whom 
the net benefit of treatment is positive, there is a need to select the appropriate medication 
and dosage. A few factors influenced our decision to prioritize the second evidence gap 
for this dissertation. The characteristics of treated and untreated residents, as well as 
those receiving DOACs versus warfarin, were summarized in Aim 1. Similar 
distributions of stroke and bleeding risk factors among DOAC and warfarin users 
suggested clinical equipoise, an inference reinforced by the close to equivalent fractions 
of the population using each class of anticoagulants as of the end of 2016. Furthermore, 
one of the strongest pharmacoepidemiologic study designs (i.e., active-comparator new-
user)68 was well-suited to addressing the question of comparative safety and effectiveness 
between DOACs and warfarin. In contrast, a comparison of users versus non-users poses 
challenges associated with the construction of an unbiased comparison group that 
overcomes the prominent threat to validity posed by selection bias in such designs. 
Recognizing that clinical trials are very unlikely to be conducted in the nursing home 





dwelling populations) are positioned to serve as the backbone of the evidence to guide 
anticoagulant selection for this population. 
Limitations and strengths 
Although accepted pharmacoepidemiologic practices were applied throughout this 
dissertation, each of the studies involved observational research using secondary data 
sources, and as such, several limitations require acknowledgement. First, anticoagulant 
use was operationalized using dispensing dates and number of days supplied recorded in 
Medicare Part D claims. Actual medication use may deviate from observed dispensing 
patterns, although the issue of patient nonadherence is largely mitigated in nursing home 
settings by the nature of medication administration by facility staff. Deviations from 
dispensing patterns may occur due to transitions of care into and out of settings (e.g., 
hospitals, SNFs) where medications are dispensed and not reimbursed through Medicare 
Part D. To avoid prematurely censoring residents in hospital settings due to apparent 
discontinuation (depletion of their outpatient anticoagulant supply), we carried forward 
the supply available at the time of entry into the hospital/SNF until the end of the stay. 
Anticoagulant use may have also been misclassified if the medication was filled using 
health insurance (or cash) other than Medicare. All residents were required to be enrolled 
in Medicare Part D and to have had at least one medication dispensing, at least partially 
mitigating concerns of unobserved anticoagulant use. Finally, certain forms of non-
standard medication taking behavior are typically not observable in Part D records (e.g., 





The study population for this dissertation included nursing home residents with 
diagnosed atrial fibrillation. To increase specificity, only residents with both a qualifying 
Medicare Part A diagnosis (atrial fibrillation or atrial flutter) and a qualifying MDS 3.0 
diagnosis (dysrhythmia, atrial fibrillation, or atrial flutter) in the prior year were eligible 
for the study. As a consequence, only residents who had been discharged from a hospital 
or SNF in the prior year would be eligible for inclusion. Selection bias may have been 
introduced if long-term nursing home residents who did not recently contact acute or 
post-acute care differed in the prevalence of anticoagulant use from those residents who 
had a hospitalization or SNF stay. Our concerns regarding the inclusion of residents with 
only a hospital diagnosis centered on the potential for a diagnosis based on transient 
episode in the inpatient setting, while the majority of MDS diagnoses were non-specific 
(i.e., dysrhythmia). In practice our concerns were valid and the requirement for diagnoses 
in both settings justified, as only 27% of residents with a hospital diagnosis but no MDS 
diagnosis received oral anticoagulants, suggesting that a sizable fraction likely had a 
transient acute episode. However, it is also possible that residents did not have adequate 
follow-up for chronic atrial fibrillation after the transition in care back to the nursing 
home setting. 
Outcome misclassification constituted a threat to validity for the comparative 
analyses performed in Aim 3. Validated algorithms relying on ICD-9 and ICD-10 codes 
from Medicare Part A claims were used to operationalize clinical outcomes. Although 
coding practices may change over time and most algorithms have not been validated 





Mappings (GEMs)128 to translate the ICD-9 based algorithms to ICD-10. Because of the 
close conceptual relationship between the ICD-9 and ICD-10 codes comprising our 
outcome definitions, and with the use of GEMs, positive predictive values of the 
algorithms were expected to be comparable to the original validation studies. Of 
potentially greater significance was under-detection of clinical outcomes which either 
were sufficiently minor to not precipitate a hospitalization or that were severe enough to 
cause death. In both cases, residents would not enter the hospital and generate a Medicare 
Part A claim from which the outcome could be identified. Our net clinical benefit 
composite outcome, which included all-cause mortality, shed some light on the 
possibility of differential incidence of severe clinical events resulting in death. The lower 
mortality and composite event rates with the DOACs versus warfarin suggested 
unobserved severe clinical events resulting in death may have been more common in the 
warfarin group. However, imbalance in unmeasured confounding variables associated 
with mortality could also explain this finding. 
Unmeasured or residual confounding represents an additional threat to validity for 
the comparative effectiveness research conducted in Aim 3. Confounding by indication is 
typically most pronounced in comparisons across indications, between prevalent users, or 
between treated and untreated populations. Our new-user, active comparator design, was 
well-suited to dealing with confounding by indication.68 Our analytic strategy, propensity 
score matching, was applied for the purpose of assembling balanced treatment and 
comparison groups to thwart confounding as a threat to validity.69,70 Empirically, we 





clinical risk factors for the outcomes under investigation. Although unmeasured 
confounding cannot be entirely excluded as a possible explanation for the observed 
results, the results for falsification outcomes (pneumonia, COPD) not known to be 
associated with either of the classes of oral anticoagulants under study were not 
indicative of strong unmeasured confounding. 
This dissertation had several strengths. By linking multiple the MDS 3.0 with 
Medicare files we were able to develop a near complete picture of a national population 
of residents’ demographic, clinical, and functional characteristics and then follow 
residents longitudinally throughout transitions in care to acute, post-acute, and long-term 
care settings. The linkage to facility and county level files enabled multilevel modeling 
analyses which yielded insights into possible hot-spots for quality improvement (i.e., 
geographies with low anticoagulant utilization), while also providing important 
confirmation that widespread variation in prescribing is not systematic in nature and in 
doing so underscoring the need for best practice standards specific to the nursing home. 
Finally, the contemporary nature of the data used for this dissertation increases the 
potency of the findings for motivating clinical and policy changes.  
Implications and future research 
The output from the three specific aims of this dissertation have important clinical 
and research implications. 
Clinical implications 
The findings of this dissertation are expected to influence clinical practice and 





committees. First, the prevalence of off-label DOAC dosing was higher in the nursing 
home than in the community. Individuals receiving DOAC doses that were not aligned 
with recommended dosing had higher rates of ischemic stroke in the case of underdosing 
and higher rates of hemorrhage in the case of overdosing. Targeted quality improvement 
activities by individual facilities, their corporate parents, and their clinical consultants 
(e.g., consultant pharmacists) may be warranted to address dosing alignment. Second, 
results of our comparative effectiveness research should reassure clinicians that DOACs 
can be confidently used with equal or greater benefit than warfarin. At the same time, our 
findings suggested that providers may be better selecting candidates for warfarin therapy 
and/or better managing warfarin users, as residents initiating warfarin after DOAC 
utilization was widespread achieved lower stroke rates than those initiating warfarin prior 
to the widespread utilization of DOACs. Individual comparisons of apixaban, 
rivaroxaban, and dabigatran versus warfarin by dose should be used to inform shared 
decision-making processes for drug and dose selection. 
Research implications 
 This dissertation establishes a foundation for multiple avenues of future research. 
First, additional observational research is needed to inform the critical decision of 
whether or not to anticoagulate nursing home residents with atrial fibrillation. This will 
involve comparisons of users of anticoagulants, by medication, versus similar residents 
who are not receiving oral anticoagulants. To overcome the challenge of confounding by 
indication, researchers should consider the advantages of using antiplatelets as an active 





preferences across nursing homes as an instrumental variable. Subgroup analyses will be 
important for identifying subgroups of residents with distinctly higher or lower risk of 
specific outcomes in the presence or absence of treatment. Beyond observational 
research, randomized clinical trials would provide gold standard level of evidence to 
guide treatment. Trials involving DOACs would be of highest value if multiple doses 
were evaluated separately for subgroups of residents with different levels of renal 
impairment. This level of trial-based research could be used to change the drug 
prescribing information approved by the FDA. 
In addition to comparative effectiveness research, predictive modeling is an 
important next step for the purpose of developing risk scoring algorithms tailored to the 
nursing home population. If a parsimonious set of routinely available risk factors were to 
be assembled into a predictive algorithm with acceptable accuracy, opportunities for 
adapting the algorithm for clinical use should be explored with a goal of ultimately 
evaluating the utility within the context of resident-centered shared decision-making. 
Other important complimentary research efforts could improve the utility of the findings 
from this dissertation. Validation studies of ICD-10 code based outcome definitions for 
the nursing home population could illuminate the extent to which minor clinical events 
and fatal clinical events are under-detected by hospital-based ICD coding algorithms. 
Qualitative research is also needed to better understand resident, family member, and 
provider perceptions of and willingness to participate in a shared decision-making 






 In summary, the three studies comprising this dissertation updated and advanced 
the field’s understanding of one of the most effective25 and highest risk classes138 of 
medications for a particularly vulnerable and challenging patient population. The 
proportion of nursing home residents with atrial fibrillation was found to have increased 
from 30% in 200449 to 48% by the end of our study period (2016). Simultaneously, the 
uptake of a novel class of medications (DOACs) was found to have displaced 
approximately half of the warfarin utilization in the nursing home setting, while also 
contributing to an increase in anticoagulant use of ~5% between 2014 and 2016. Our 
research demonstrated the absence of a systematic approach to anticoagulant use in 
United States nursing homes. We then began to address the glaring need for evidence to 
inform anticoagulant selection by evaluating the comparative safety and effectiveness of 
individual DOACs versus warfarin. Our findings suggested that overall, DOACs were 
being used with equal or greater benefit than warfarin, but that there is likely opportunity 
to improve outcomes with DOAC use by aligning dosing with FDA approved labeling. 
Future research should prioritize additional comparative effectiveness research and the 
development of predictive algorithms specific to the nursing home setting to identify 
subgroups of residents most likely to benefit from treatment and to package this 
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